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Abbreviations 
Ang-1, -2  Angiopoietin-1, -2 
ANOVA  analysis of variance 
AUC  area under the curve 
CI  confidence interval 
ELISA  enzyme-linked immunosorbent assay 
Flt-1, -4  fms-like tyrosine kinase-1, -4 (see VEGFR-1 and -3) 
hCG   human chorionic gonadotropin 
HIF-1α, -1β  hypoxia-inducible transcription factor-1α, -1β 
HSPG   heparan sulfate proteoglycan 
IUGR  intrauterine growth retardation 
NO  nitric oxide 
NRP-1, -2  neuropilin-1, -2 
OR  odds ratios 
PAPP-A  pregnancy-associated plasma protein-A 
PBS  phosphate buffered saline 
PlGF   placental growth factor  
ROC curve  receiver operating characteristic –curve 
SD  standard deviation 
SGA   small for gestational age 
sTie-1, -2  soluble Tie-1, -2 (see also Tie-1 and Tie-2) 
sVEGFR-1, -2 soluble VEGFR-1, -2 (see also VEGFR-1, -2) 
Tie-1  tyrosine kinase with immunoglobulin and epidermal growth  
factor-like extracellular domains  
Tie-2  tyrosine kinase with epidermal growth factor homology 
VEGF-A,-B,-C,-D,-E,-F  vascular endothelial growth factor -A, -B, -C, -D, -E, -F 
VEGFR-1, -2, -3  vascular endothelial growth factor receptor-1, -2, -3 
 
 
  
Definitions 
Apgar score Measure of a newborn’s immediate well-being determined by evaluating it on the 
basis of five criteria (breathing, pulse rate, reflexes, muscle tone and skin color) using 
scale from 0 to 2, the maximum score being 10 which represents an optimal condition. 
Birth Process resulting in infant with a gestational age of ≥ 22+0 weeks or weight ≥ 500 g. 
CBA/J x DBA/2 Mouse model of immunologically mediated pre-eclampsia (DBA/J –mated CBA/J –
female mice). 
Eclampsia Occurrence of seizures in pregnant women diagnosed with pre-eclampsia and unre-
lated to other origins. 
Ex vivo Experimentation or measurements performed in/on tissue in artificial environment 
outside the organism with minimum alteration of natural conditions. “Ex vivo” –
conditions allow experimentation under more controlled conditions than often pos-
sible in “in vivo” –experiments (see below).  
HELLP syndrome Complication of pre-eclampsia with hemolysis, elevated liver-enzymes and low plate-
let count. 
In utero ‘In the uterus’ – Expression referring to unborn child (in legal context) or state of 
embryo / fetus (biological context). 
In vitro Experimentation conducted using components of organism, isolated from their usual 
biological context, in order to permit a more detailed or more convenient analysis 
than the one conducted with whole organisms. 
In vivo Experimentation conducted with a whole, living organism in its normal, intact state, 
as opposed to partial or dead organism. 
IUGR ‘Intrauterine growth retardation’ – failure of the fetus / newborn to achieve geneti-
cally determined individual growth potential in utero. 
LBW ‘Low birthweight’ – live-born infant with a birthweight of < 2500 g. 
locus Position that a given gene occupies on a chromosome. (plural: “loci”) 
Maternal mortality Number of maternal deaths during pregnancy or within the following 6 weeks divided 
by 100000 live born children. Accidental or violent deaths are excluded from the total. 
Nullipara Woman who has never given birth to a child. 
PBS ‘Phosphate buffered saline’ – isotonic medium solution for cell cultures and washing 
of tissue sections, containing the following chemicals in the given concentrations (pH 
= 7.4): 0.14 M NaCl, 2.7 M KCl, 0.01 M Na2HPO4, and 1.76 M KH2PO4. 
Perinatal mortality Number of stillbirths and early neonatal deaths during the first week of life divided by 
number of births during the same time period (usually statistical year). ‘Neonatal 
mortality’ is derived similarly from number of deaths during the first 4 weeks of life. 
Premature infant Infant born < 37+0 weeks of gestation. Newborn with a weight of ≤ 1500 g or a gesta-
tional age of < 32+0 weeks at birth is referred to as ‘small premature infant’. 
Preterm delivery Length of gestation < 37+0 weeks at delivery. 
Primipara Woman who is pregnant / has been delivered of a child for the first time. 
Puerperium State of a mother during childbirth or immediately thereafter extending for about six 
weeks, until the return of a normal uterine size. Synonymic to ‘postpartum period’, 
whereas ‘postnatal period’ is an equivalent term referring to the infant. 
SGA ‘Small for gestational age’ – small infant who has failed to achieve a gender-specific 
weight threshold, usually defined as the 10th percentile of the population. 
Stillbirth Birth of a child showing no evidence of life (breathing, heartbeat, pulsation of umbili-
cal cord or movement of voluntary muscles) but fulfilling the criteria of ‘birth’. 
Term delivery Length of gestation ≥ 37+0 and > 42+0 weeks at delivery. 
VEGF Trap Soluble VEGF receptor –like fusion protein containing the domain 2 of VEGFR-1 and 
the domain 3 of VEGFR-2, fused with an Fc fragment (AVE0005 or aflibercept). 
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Abstract 
Pre-eclampsia is a pregnancy complication that 
affects about 5% of all pregnancies. It is known to 
be associated with alterations in angiogenesis-
related factors, such as vascular endothelial 
growth factor (VEGF). An excess of anti-
angiogenic substances, especially the soluble 
receptor-1 of VEGF (sVEGFR-1), has been ob-
served in maternal circulation after the onset of 
the disease, probably reflecting their increased 
placental production. Smoking reduces circulat-
ing concentrations of sVEGFR-1 in non-pregnant 
women, and in pregnant women it reduces the 
risk of pre-eclampsia. Soluble VEGFR-1 acts as a 
natural antagonist of VEGF and placental growth 
factor (PlGF) in human circulation, holding a 
promise for potential therapeutic use. In fact, it 
has been used as a model to generate a fusion 
protein, “VEGF Trap”, which has been found 
effective in anti-angiogenic treatment of certain 
tumors and ocular diseases.  
In the present study, we evaluated the poten-
tial use of maternal serum sVEGFR-1, Angio-
poietin-2 (Ang-2) and endostatin, three central 
anti-angiogenic markers, in early prediction of 
subsequent pre-eclampsia. We also studied 
whether smoking affects circulating sVEGFR-1 
concentrations in pregnant women or their first-
trimester placental secretion and expression in 
vitro. Last, in order to allow future discussion on 
the potential therapy based on sVEGFR-1, we 
determined the biological half-life of endogenous 
sVEGFR-1 in human circulation, and measured 
the concomitant changes in free VEGF concen-
trations. Blood or placental samples were col-
lected from a total of 268 pregnant women be-
tween the years 2001–2007 in Helsinki Univer-
sity Central Hospital for the purposes above. The 
biomarkers were measured using commercially 
available enzyme-linked immunosorbent assays 
(ELISA). 
For the analyses of sVEGFR-1, Ang-2 and 
endostatin, a total of 3 240 pregnant women in 
the Helsinki area were admitted to blood sample 
collection during two routine ultrasound-
screening visits at 13.7 ± 0.5 (mean ± SD) and 
19.2 ± 0.6 weeks of gestation. Of them, 49 
women later developing pre-eclampsia were 
included in the study. Their disease was further 
classified as mild in 29 and severe in 20 patients. 
Isolated early-onset intrauterine growth retarda-
tion (IUGR) was diagnosed in 16 women with 
otherwise normal medical histories and uncom-
plicated pregnancies. Fifty-nine women remain-
ing normotensive, non-proteinuric and finally 
giving birth to normal-weight infants were 
picked to serve as the control population of the 
study.  
Maternal serum concentrations of Ang-2, 
endostatin and sVEGFR-1, were increased al-
ready at 16–20 weeks of pregnancy, about 13 
weeks before the clinical manifestation of pre-
eclampsia. In addition, these biomarkers could 
be used to identify women at risk with a moder-
ate precision. However, larger patient series are 
needed to determine whether these markers 
could be applied for clinical use to predict pre-
eclampsia. 
Intrauterine growth retardation (IUGR), es-
pecially if noted at early stages of pregnancy and 
not secondary to any other pregnancy complica-
tion, has been suggested to be a form of pre-
eclampsia compromising only the placental suffi-
ciency and the fetus, but not affecting the mater-
nal endothelium. In fact, IUGR and pre-
eclampsia have been proposed to share a com-
mon vascular etiology in which factors regulating 
early placental angiogenesis are likely to play a 
central role. Thus, these factors have been sug-
gested to be involved in the pathogenesis of 
IUGR. However, circulating sVEGFR-1, Ang-2 
and endostatin concentrations were unaffected 
by subsequent IUGR at early second trimester. 
Furthermore, smoking was not associated with 
alterations in maternal circulating sVEGFR-1 or 
its placental production. 
The elimination of endogenous sVEGFR-1 
after pregnancy was calculated from serial sam-
ples of eight pregnant women undergoing elec-
tive Caesarean section. As typical for proteins in 
human compartments, the elimination of 
sVEGFR-1 was biphasic, containing a rapid half-
life of 3.4 h and a slow one of 29 h. The decline in 
sVEGFR-1 concentrations after mid-trimester 
legal termination of pregnancy was accompanied 
with a simultaneous increase in the serum levels 
of free VEGF so that within a few days after 
pregnancy VEGF dominated in the maternal 
circulation. Our study provides novel informa-
tion on the kinetics of endogenous sVEGFR-1, 
which serves as a potential tool in the develop-
ment of new strategies against diseases associ-
ated with angiogenic imbalance and alterations 
in VEGF signaling. 
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Introduction 
Angiogenesis, defined as growth of new vessels 
sprouting from pre-existing ones, is essential in 
fetal development, but aside from pathologic and 
trauma conditions, it is mainly limited to the 
female reproductive cycle in adults. Pathologic 
angiogenesis is characterized as either excessive 
or inadequate neovascularization. It is a crucial 
pathophysiological event in malignant, ischemic, 
infectious, immune and inflammatory disorders 
(Carmeliet. 2005). Angiogenesis is tightly regu-
lated by a number of pro- and anti-angiogenic 
factors, and vascular endothelial growth factor 
(VEGF) is a key mediator of several angiogenic 
signals. 
In human physiology, the most remarkable 
scene of angiogenesis is the formation of the 
placenta and fetus. Successful implantation, 
placentation and the following gestation are de-
pendent on vascular development and adapta-
tion. Both VEGF and its soluble receptor-1 
(sVEGFR-1), acting as a natural antagonist of 
VEGF, are highly expressed in the placenta 
throughout the gestation (Vuorela et al. 1997, 
Sharkey et al. 1993, Clark et al. 1996, Vuorela et 
al. 2000). Beginning from early pregnancy, 
sVEGFR-1 is secreted by the trophoblasts, and it 
can be detected as constantly elevating concen-
trations in the maternal circulation already about 
a month following the conception (Levine et al. 
2004, McKeeman et al. 2004, Powers et al. 2005, 
Molskness et al. 2004). 
Pre-eclampsia affects about 5% of all preg-
nancies, and it is the most common cause of 
maternal and perinatal mortality and morbidity 
in the developing countries (Khan et al. 2006, 
Duley. 2009). The pathophysiology of the disease 
has been characterized as placental hypoperfu-
sion and ischemia, starting already at the im-
plantation and early pregnancy. The etiology of 
pre-eclampsia has been intensively studied, but 
still the final cause remains unknown. So far, the 
delivery of the placenta is the only definitive cure 
for the disorder (Datta. 2004).  
Pre-eclampsia is characterized by an angio-
genic imbalance, which has been proposed to 
first act on the placental level, but subsequently 
become evident also on the systemic level. As a 
result, there is an overall maternal endothelial 
dysfunction, which has been associated with the 
clinical manifestations of the syndrome (Roberts 
et al. 1989, de Groot and Taylor. 1993). An excess 
of anti-angiogenic factors, especially sVEGFR-1, 
has been found in the maternal circulation after 
the onset of the disease, probably reflecting an 
increased placental production of this pregnancy 
–induced protein (Levine et al. 2004, Chaiwora-
pongsa et al. 2004, Koga et al. 2003, Maynard et 
al. 2003).  Indeed, the vascular endothelium is 
considered as the target organ of the biochamical 
alterations in the placenta during pre-eclampsia. 
Besides the angiogenic imbalance, the un-
derlying events in the placental morphology have 
been proposed to be associated with some other 
etiologies. Most notably, genetic and immu-
nological factors have been shown to contribute 
to the risk of pre-eclampsia (Chappell and 
Morgan. 2006, Dekker and Robillard. 2007). 
Interestingly, smoking has been observed to 
reduce the risk of pre-eclampsia in pregnant 
women (Conde-Agudelo and Belizan. 2000). In 
non-pregnant women, it affects circulating 
sVEGFR-1 concentrations, which have been 
noted to be lower than in non-smokers (Belgore 
et al. 2000, Schmidt-Lucke et al. 2005). 
Intrauterine growth retardation (IUGR), es-
pecially if noted at early stages of pregnancy and 
not secondary to any other pregnancy complica-
tion, has been suggested to be a form of pre-
eclampsia not affecting the maternal endothe-
lium (Regnault et al. 2002). Based on poor re-
modeling of the placental bed spiral arteries, 
which have been detected in both IUGR and pre-
eclampsia (Khong et al. 1986), they have been 
proposed to share a common vascular etiology 
(Regnault et al. 2002, VanWijk et al. 2000, 
Myatt. 2002). Thus, factors regulating angio-
genesis in the early placenta are likely to play a 
central role also in the pathogenesis of IUGR. 
As pre-eclampsia is associated with increases 
in anti-angiogenic substances, the phenomenon 
could possibly be detectable in the maternal cir-
culation already in early pregnancy preceding the 
development of the symptoms, perhaps even 
providing a predictive tool for identifying women 
at risk. The protective effect of smoking in pre-
eclampsia might also be mediated by the angio-
genic imbalance. Furthermore, such principles 
could hold a promise for future interventions on 
the angiogenesis-related factors. 
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Literature Review 
 
1. Angiogenesis 
Aside from pathologic and traumatic conditions, 
blood vessel development is mostly limited to the 
reproductive track in adults. Female reproduc-
tive organs, the ovaries and the uterus, undergo 
sequential growth and regression during the 
menstrual cycle, maintaining their functions with 
a careful balance in the vascular systems (Carme-
liet. 2005). Successful implantation, placentation 
and the following gestation are dependent on 
vascular development and adaptation.  
1.1. Angiogenesis and vasculogenesis 
Vasculogenesis includes the formation of a 
primitive vascular capillary network, achieved by 
mesoderm-derived precursor cells, with differen-
tiation and proliferation. This primitive network 
is further remodeled to a complexed circulatory 
system by creating vascular sprouts from pre-
existing microvessels. This process is referred to 
as angiogenesis, which begins with capillary 
sprouting and culminates in the formation of a 
new microcirculatory bed composed of arterioles, 
capillaries, and venules (Risau. 1997).  
1.2. Mechanisms and regulation of 
angiogenesis 
The initiation of angiogenesis consists of three 
processes: break down of the basement mem-
brane of the existing vessel, migration of their 
endothelial cells towards an angiogenic stimulus, 
and proliferation of the endothelial cells 
(Schoenwolf et al. 2009).  
 
 
 
 
 
 
Angiogenesis occurs by at least the four following 
ways (Risau. 1997, Schoenwolf et al. 2009):  
 
1. sprouting - mostly during neovasculari-
zation of vascular tissue, 
2. intussusception – internal division of 
the vessel by endothelial cells resulting 
in the vessel split in two, 
3. elongation or widening – lengthways 
growth of the vessel without formation 
of new vascular junctions, and 
4. incorporation of circulating endothelial 
cells into pre-existing vessels. 
 
Numerous factors regulate the angiogenic proc-
ess in human tissues. They comprise peptide 
growth factors, hormones, cytokines, chemical 
substances and physical stimuli (Risau. 1997). 
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2. Uncomplicated pregnancy 
2.1. Beginning of pregnancy 
The gestation period from the beginning of pre-
vious menstruation until birth usually lasts for 
280 days, accounting for 40 gestational weeks. 
The first 10 weeks of pregnancy is referred to as 
the embryonic period which is followed by the 
fetal period. The 9-month gestation is divided 
into three 3-month trimesters (Schoenwolf et al. 
2009). 
Fertilization occurs at the beginning of the 
third week of the following pregnancy. After 
fertilization, the zygote travels from the uterine 
tube going through rapid mitotic divisions. Fi-
nally, the formed blastocyst enters the uterine 
cavity, which serves as the implantation site and 
is essential for normal pregnancy. 
2.1.1. Implantation 
About the 20th day of preganancy, the tro-
phoblast cells of the blastocyst begin to invade 
the maternal endometrium by penetrating be-
tween the endometrial cells. These trophoblasts 
later fuse to form an expanding peripheral layer 
of multinucleated syncytiotrophoblasts, called 
the placental syncytium. The trophoblasts from 
the wall of the blastocyst remain unicellular, 
thereafter referred to as cytotrophoblasts, which 
act as a stem cell population. On about the 23rd 
day the blastocyst is deeply embedded in the 
endometrium, which initiates the lacunar stage 
of trophoblast development. Implantation is 
considered complete three days later, around the 
12th day post-conception, at the end of the 4th 
gestational week (Schoenwolf et al. 2009). 
2.1.2. Formation of placenta 
The development of the placenta begins as the 
implanting blastocyst induces a response in the 
uterine endometrium called the decidual reac-
tion, decidualization. Cells in the endometrial 
stroma accumulate lipid and glycogen and the 
endometrium thickens, becoming also a highly 
vascularized tissue, thereafter called “decidua”.  
During the first weeks the embryo is nourished 
through simple diffusion. However, later on, due 
to its rapid growth, it needs a more powerful gas 
and nutrient exchange system, which is made 
possible by the development of the uteroplacen-
tal circulation system. The early placenta devel-
ops under hypoxic conditions (Schoenwolf et al. 
2009). 
Already upon the implantation, the cytotro-
phoblasts proliferate to form finger-like out-
growths giving rise to the villous trees of the 
placenta. The outgrowths, containing only cytot-
rophoblasts, appear soon after the first signs of 
primitive uteroplacental circulation. These struc-
tures are called primary chorionic stem villi, 
which are further transformed into secondary 
chorionic stem villi during the early 5th week of 
pregnancy. The process is initiated by proliferat-
ing extraembryonic mesoderm, which invades 
the cores of primary villi.  
At the end of the 5th week the villus meso-
blast, mesodermal core of secondary villus, dif-
ferentiates into connective tissue and blood ves-
sels. They connect up with the embryonic blood 
vessels, forming the basis of tertiary stem villi, 
which contain differentiated blood vessels 
(Schoenwolf et al. 2009). All subsequent vascu-
larized villi are subtypes of them (Kingdom et al. 
2000). From there on, a total of four layers must 
be passed in order for gases, nutrients, and waste 
products to diffuse through the maternal and 
fetal blood: capillary endothelium of the villus, 
loose connective tissue surrounding the endothe-
lium, cytotrophoblast and syncytiotrophoblast. 
The mesenchymal cells hold a potential to 
further differentiate into angioblasts, endothelial 
cells and hematopoietic stem cells. The cells as-
sociated with the vasculature are derived from 
mesenchymal cells, which have first differenti-
ated from the extraembryonic mesoderm. In 
addition, mesenchyme-derived macrophages, 
called Hofbauer cells, express angiogenic growth 
factors in the mesenchyme of the villi for the 
paracrine initiation of vasculogenesis 
(Schoenwolf et al. 2009). 
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2.1.3. Development of uteroplacental circulation 
In the uteroplacental circulation system the cir-
culations of the mother and that of the embryo 
become closer to each other, allowing exchange 
of gases and metabolites via diffusion. During 
pregnancy the uterine circulation is highly adap-
tive to the growing metabolic demands of the 
fetus. Maternal blood flows into the intervillous 
spaces through the spiral arterioles, which 
branch from the uterine arteries. The deoxygen-
ated blood leaves the placenta via the uterine 
venules located in the periphery of the intervil-
lous space. The placental blood flow can rise up 
to 6 000 mL in a minute and the pressure in the 
spiral arteries to 70 mmHg from which it falls to 
only 10 mmHg in the intervillous space. The 
blood in the maternal side of the placenta is ex-
changed up to three times per minute. 
The development of the uteroplacental circu-
lation starts at the middle of the 4th week of ges-
tation when irregular spaces appear in the syn-
cythiothrophoblast and they soon join together 
to form lacunae. These lacunae are originally 
filled with tissue fluids and uterine secretions, 
but later on they anastomose with maternal ca-
pillaries. A week later fetal blood vessels and 
tertiary stem villi, projecting into the trophoblas-
tic lacunae, begin to develop. 
Maternal capillaries near the syncytiotro-
phoblasts expand to form maternal sinusoids, 
and the lacunae are fulfilled with blood around 
the beginning of the 6th week of pregnancy. At the 
end of the pregnancy the lacunae communicate 
with each other forming a connected system 
delimited by the syncytiotrophoblast and re-
ferred to as the intervillous space. 
The anastomoses between trophoblastic la-
cunae and maternal sinusoids continue to de-
velop during the next few days, when the cytot-
rophoblasts begin to proliferate locally and form 
the villous structures of the placenta. The first 
blood vessels are completed by the end of the 7th 
week establishing the uteroplacental circulation 
(Schoenwolf et al. 2009). 
2.1.4. Development of fetal vasculature 
Formation of the fetal vasculature starts at the 
early 5th week of gestation. After differentiation, 
the endothelial cells organize into tiny capillar-
ies, which then lengthen and interconnect. This 
de novo formation of blood vessels, vasculogene-
sis, supplies the primary vascular network in the 
yolk sac, connecting stalk and the chorionic villi 
already by the end of the 5th week. This network 
transporting fetal erythrocytes further develops, 
growing and spreading by different mechanisms 
throughout the embryo (Schoenwolf et al. 2009, 
Demir et al. 1989). Later, during the first trimes-
ter, new fetal vessels are formed within the villi 
by branching angiogenesis. 
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Figure 1. The placental circulation and the fetoplacental unit. 
Copyright© 2011 Hannu Koponen. All rights reserved. 
 
Figure 1. The placenta is a combination of maternal and embryonic tissues. It transports nutrients, respiratory gases 
and waste products between the mother and the fetus from the 6th week of gestation until birth. During the first events of 
implantation, the cytotrophoblasts start to proliferate to form finger-like outgrowths giving rise to the villous trees of the 
placenta. Only about a week from the implantation, at late 4th week of pregnancy, the trophoblastic lacunae within the 
syncytiotrophoblasts anastomose with maternal capillaries initiating the development of the uteroplacental circulation. 
The first blood vessels are completed by the end of the 7th week establishing the uteroplacental circulation. Simulta-
neously, also the fetal blood vessels have begun to develop from the 5th week of gestation. 
Maternal blood enters the intervillous space via spiral arterioles, and flows to the blood sinus surrounding the chorionic 
villi due to the relatively high pressure. As the pressure decreases, the deoxygenated blood leaves the placenta through 
the endometrial venules.  
Deoxygenated fetal blood enters the placenta via two umbilical arteries, which branch radially to form chorionic arteries 
at the junction of the umbilical cord and the placenta. The following vessels travel embedded in the chorion, which is the 
fetal part of the placenta. They further branch into cotyledon arteries and eventually form an extensive arteriocapillary 
venous system, passing through the capillaries of the chorionic villi projecting into the maternal portion of the placenta, 
the decidua, bringing the fetal blood extremely close to maternal blood.  
Fetal and maternal blood are separated by "placental barrier” the thinnest part of which contains only the syncytiotro-
phoblast layer, the merged basal membrane and the endothelium of the fetal vessels, the latter of which retains the fetal 
blood inside them while the maternal blood flushes the chorionic villi with faily high blood pressure. This is the site of 
oxygen and nutrient transport, after which fetal blood leaves the placenta via the umbilical vein, leading back to the fetus. 
Materials are exchanged between the fetal capillary bed and the maternal sinus by diffusion, active transport and selec-
tive absorption. 
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2.2. Adaptation of maternal and 
uteroplacental circulation 
The placental villi reach their maximal length 
during the first trimester. During the second 
trimester, the placenta exhibits dramatic growth 
accompanied by a substantial increase in the 
vascular volume. During the third trimester, 
except for the last gestational weeks, the villi also 
form numerous slender side branches called 
mature intermediate villi, and they further start 
to produce small secondary branches called ter-
minal villi. This process results in changes in the 
villous vascular architecture, which then devel-
ops via non-branching angiogenesis, i.e. increas-
ing the size of the existing vessels. As the gesta-
tion proceeds, these terminal capillaries dilate 
focally to form large sinusoids in order to opti-
mize the diffusional gas exchange between the 
fetal and maternal circulations (Schoenwolf et al. 
2009). 
2.2.1. Remodeling of spiral arteries 
The remodeling of the maternal spiral arteries 
takes place towards the end of the first trimester. 
During this process the extravillous, so-called 
“endovascular” cytotrophoblast cells invade these 
narrow, highly coiled, muscular vessels of the 
decidua and the inner third of the myometrium 
(Burton et al. 2009, Jauniaux and Greenough. 
2007). They transform into endothelial-pheno-
type cells expressing typical endothelial markers 
and replace the maternal endothelium of the 
spiral arteries in a process called “pseudovascu-
logenesis” (Zhou et al. 1997b).  
Due to the trophoblast invasion, the mater-
nal spiral arteries are widened to form high-
caliber ("high-flow"), low-resistance channels, 
which are no longer responsive to vasomotor 
influences. Concomitantly, a mixture of fibrinoid 
and fibrous tissue replaces the normal musculo-
elastic tissue around the vessels. During the early 
second trimester, the trophoblasts have invaded 
about 40-60 spiral arterioles of which 12-15 may 
be called major arteries. 
2.2.2. Hemodynamic and cardiovascular 
adaptation 
Pregnancy has been referred to as “the time of 
special physiological stress” during female life. 
The demands of the growing fetus are mediated 
via the placenta, which serves as the pathway of 
nutrient supply, gas exchange and metabolite 
transfer. The adaptation of the maternal physiol-
ogy to these needs is ensured by hormonal 
changes beginning from fertilization and con-
tinuing until delivery. 
Maternal adaptation to pregnancy is associ-
ated with tremendous changes namely in the 
cardiovascular system, as the circulation be-
comes hyperdynamic. This phenomenon is char-
acterized by increases in plasma volume, heart 
rate and cardiac output, and reductions in blood 
pressure and vascular resistance. The increase in 
maternal blood volume begins in the first trimes-
ter, increases rapidly during the second trimester 
and continues, although much more moderately, 
until term (Duvekot and Peeters. 1994).  
Cardiac output begins to increase in early 
pregnancy initiated by an increase in the heart 
rate and followed by an elevation in the stroke 
volume (Hunter and Robson. 1992). Cardiac 
output tends to rise until the middle of preg-
nancy (Duvekot and Peeters. 1994), eventually 
being nearly 50% more than that before the 
pregnancy (Hunter and Robson. 1992). The in-
crease in the heartbeat, however, remains less 
than 20% of its non-pregnant level (Datta. 
2004).  
The maternal systemic blood pressure de-
clines after the beginning of pregnancy, reaching 
a minimum during the second trimester (Duve-
kot and Peeters. 1994). After that, the blood 
pressure usually returns to its baseline level at 
term (Duvekot and Peeters. 1994). The diastolic 
pressure is usually reduced more than the sys-
tolic one, and the reduction is typically about 5-
10 mmHg at the second trimester. Because of the 
hemodynamic changes above, peripheral vascu-
lar resistance lowers as pregnancy advances (Du-
vekot and Peeters. 1994). 
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There is an increase in the myocardial contrac-
tility during the entire pregnancy, causing the 
development of mild ventricular hypertrophy in 
the heart (Duvekot and Peeters. 1994, Hunter 
and Robson. 1992). The most visible alterations 
in cardiovascular parameters have been detected 
within 2 weeks postpartum, and only a minor 
ventricular hypertrophy persists 5 months after 
pregnancy (Duvekot and Peeters. 1994) 
Renal plasma flow is elevated due to vaso-
dilatation in the kidneys. As a result, the glo-
merular filtration rate increases in early preg-
nancy slightly declining towards term (Jeyabalan 
and Conrad. 2007). Minor excretion of proteins 
(<300 mg / 24h) into urine is a normal finding 
during pregnancy (Taylor and Davison. 1997). 
Blood flow to the uterus, kidneys and breasts 
increase during the gestation. Uterine vascular 
resistance is lower than that of the systemic cir-
culation, thus allowing the blood flow in uterus 
and the placenta to be elevated to a major ex-
tend. 
2.3. Parturition and puerperium 
At term, around 40 weeks of gestation, the uter-
ine starts to contract rhythmically ending in the 
delivery of the fetus. The placenta first separates 
from the decidual tissue after which it is ex-
pelled. Myometrial contractions act to constrict 
the uterine vessels to prevent excessive bleeding. 
Upon birth of the placenta, its hormonal produc-
tion naturally ends and the previous products 
disappear from the maternal circulation accord-
ing to their characteristic half-lives. For example, 
the steroid and protein hormone concentrations 
have generally reached their typical non-
pregnant concentrations during about 48 to 72 
hours after delivery, such as in the case of human 
chorionic gonadotropin (hCG; Korhonen et al. 
1997). 
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3. Pre-eclampsia 
3.1. General aspects 
Pre-eclampsia is a pregnancy complication char-
acterized by hypertension and proteinuria. The 
risk of developing this systemic syndrome is 
about 2–8%  (Duley. 2009). Especially in the 
developing countries, pre-eclampsia is a major 
cause of maternal morbidity and mortality, and 
worldwide it is one of the leading contributors to 
adverse perinatal outcomes, such as prematurity 
and intrauterine growth retardation (Khan et al. 
2006, Duley. 2009). Other hypertensive dis-
orders in pregnancy comprise pre-existing hyper-
tension and gestational hypertension. Pre-
eclampsia is commonly considered as a placental 
disorder, although despite decades of research its 
definitive etiology is still unknown. In fact, the 
delivery of the placenta remains the only known 
cure for pre-eclampsia so far (Datta. 2004). 
In Finland, the percentage of pregnant 
women diagnosed with pregnancy induced hy-
pertension, proteinuria, pre-eclampsia or ec-
lampsia based on the hospital records from 
2000, was 2.6% of all women giving birth at the 
same year (Gissler et al. 2002). However, accord-
ing to a large national population based study in 
2000–2001, which was conducted among over 3 
500 women aged 18 or older, the lifetime occur-
rence of pre-eclampsia had been about twice 
higher, 5.0% (Koponen and Luoto. 2004). In the 
same study, gestational hypertension had been 
present at some point in nearly 19% of the 
women, and the percentage was highest in the 
youngest (age < 30 years; 22%) and the low-
educated (21%) subgroups. In a tertiary referral 
center of Kuopio University Hospital nearly 
22 000 singleton, structurally and chromosom-
ally normal pregnancies were compared to those 
of female doctors and teachers during an almost 
12-year period (Heinonen and Saarikoski. 2002). 
The study found a 3.2% overall risk of pre-
eclampsia which was interestingly much lower 
among the doctors (0.9%). In the same popula-
tion, the incidence of pre-eclampsia was meas-
ured to be unaltered with the marital status of 
the pregnant women being 3.3% among the 
unmarried and 3.0% among the married women 
(Raatikainen et al. 2005).  
3.1.1. Clinical features and diagnosis of pre-
eclampsia 
Pre-eclampsia is a heterogeneous disorder mani-
festing after 20 weeks of pregnancy with a wide 
spectrum of clinical presentations (Datta. 2004, 
Steegers et al. 2010). Pre-eclampsia is defined as 
new-onset hypertension and proteinuria during 
the mid- or late gestation (Schroeder and Ameri-
can College of Obstetricians and Gynecologists. 
2002). However, how to define the syndrome of 
pre-eclampsia in the best way, and how to differ-
entiate between the mild and severe forms of the 
disease, has been debated. The updated diagnos-
tic criteria of pre-eclampsia according to Ameri-
can College of Obstetricians and Gynecologists 
are shown in Table 1 (Steegers et al. 2010, 
Table 1. Diagnostic criteria of pre-eclampsia. 
Hypertension 
Measured at least twice and 4-6 hours apart 
After 20 weeks of pregnancy and returning normal within 3 months postpartum 
Systolic blood pressure ≥ 140 mmHg and/or 
Diastolic blood pressure ≥ 90 mmHg 
  
Proteinuria 
≥ 300 mg per 24 hours / 
Urine dipstick ≥ +1 
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Schroeder and American College of Obstetricians 
and Gynecologists. 2002) 
According to some of the classification sys-
tems, proteinuria is not obligatory for the diag-
nosis of pre-eclampsia (Datta. 2004). Further-
more, in case of superimposed disease, the diag-
nostic criterion for proteinuria can be also de-
fined as “significant increase from the baseline” 
(Steegers et al. 2010).  
 
The classification of “severe” pre-eclampsia va-
ries, but one of the most commonly used criteria 
are either the blood pressure exceeding  ≥ 
160/110 mmHg and/or proteinuria ≥ 5 g during a 
24-hour collection (Datta. 2004, Steegers et al. 
2010). More detailed diagnostic signs of severe 
pre-eclampsia are defined in Table 2. 
 
 
A serious end phase of pre-eclampsia is, by defi-
nition, “eclampsia”, characterized as presence of 
tonic-clonic seizures, also known as eclamptic 
convulsions (Datta. 2004, Zeeman. 2009). In 
addition, pre-eclampsia can be accompanied 
with other neurological manifestations including 
headache, visual disturbances, lethargy and con-
fusion, or even more serious defects such as 
hemorrhagic complications, strokes or loss of 
consciousness (Zeeman. 2009). The incidence of 
eclampsia in Finland during 1990-1994 was 2.4 
per 10 000 pregnant women, accounting for a 
total of 77 women in Finland (Salmi et al. 1999). 
Eight of them had serious complications, but 
none of them died. However, the perinatal mor-
tality amongst their infants was 5%. 
Pre-eclampsia can be classified according to 
the time of its onset. The subtype is called early-
onset pre-eclampsia if the symptoms arise before 
32 gestational weeks, and late-onset if they occur 
Table 2. Diagnosis of severe pre-eclampsia. 
Severe pre-eclampsia is commonly diagnosed by the presence of one or more of the signs and 
symptoms listed in the table. The list has been modified after the practice guidelines by Ameri-
can College of Obstetricians and Gynecologists in 2002 and its update by Steegers et al. in 2010. 
Blood 
pressure 
• Systolic blood pressure ≥ 160 mmHg (and/or) 
• Diastolic blood pressure ≥ 110 mmHg 
Proteinuria 
• ≥ 3 - 5 g per 24 h (or) 
• Urine dipstick ≥ +++ in two random samples collected  4 h apart (or) 
• Sudden oliguria (urine excretion ≤ 500 mL / 24h) – especially with elevation in previous 
creatinine level 
Other end-organ damage 
Central nervous system disturbance: headache, altered vision 
Fetal compromise: IUGR, oligohydramnios 
Pulmonary edema / Cyanosis 
Epigastric or right upper quadrant  abdominal pain 
Thrombocytopenia  (platelet count >100 000 mm3) 
Liver dysfunction / HELLP syndrome 
HELLP = hemolysis, elevated liver-enzymes and low platelet count  
IUGR = intrauterine growth retardation 
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after 37 weeks of pregnancy. Early-onset pre-
eclampsia is associated with a 20-fold increase in 
maternal mortality compared with the late-onset 
form of the disease (Steegers et al. 2010). 
3.1.2. Risk factors of pre-eclampsia 
Pre-eclampsia affects about 5% of all pregnan-
cies, the incidence varying between 2-8% de-
pending on the measured population and the 
methods used (Duley. 2009, Duley et al. 2001, 
Saftlas et al. 1989).  A number of risk factors for 
pre-eclampsia have been introduced in epidemi- 
ological studies. These predisposing factors in-
clude maternal chronic disease and special char-
acteristics, genetic background and immunologi-
cal exposure, many of which are also known to be 
associated with the pathophysiology or the in-
heritance of pre-eclampsia. (Datta. 2004, Chap-
pell and Morgan. 2006, Dekker and Robillard. 
2007). A modified list of the most common risk 
factors for it is shown in Table 3. (Datta. 2004, 
Barton and Sibai. 2008, Dekker and Sibai. 2001, 
Duckitt and Harrington. 2005).  
 
 
Table 3.  Risk factors of pre-eclampsia. 
Factors predisposing to pre-eclampsia comprise of maternal special characteristics and chronic 
disease, genetic background and immunological exposure. Many of them also play a central role 
in the pathophysiology of pre-eclampsia. 
Chronic hypertension / chronic renal disease / cardiovascular disease 
Autoimmune disease / antiphospholipid  
Thrombophilia (acquired or congenital) 
Maternal pre-existing  
medical condition 
Obesity / insulin resistance / IDDM (gestational of type-1) 
Increasing maternal age / prolonging interval between pregnancies 
Nulliparity / teenage pregnancy  
Personal or family history of pre-eclampsia 
Ethnicity (Hispanic, African-American) / low maternal birthweight 
Personal and  
family history 
Adverse outcome in previous pregnancy (IUGR, abruption placenta, fetal death) 
Multiple gestation / hydatidiform moles 
Urinary tract infection 
Pregnancy-associated  
factors 
Congenital or chromosomal anomalies (trisomy 13, triploidy) / hydrops fetalis 
Nulliparity / primipaternity 
Change of partner / teenage pregnancy 
Partner who has fathered pre-eclamptic pregnancy in another women 
Partner-related 
factors 
Limited sperm exposure / donor insemination / IVF / use of donated oocytes 
IDDM = insulin-dependent diabetes mellitus 
IUGR = intrauterine growth retardation 
IVF = in vitro fertilization 
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3.1.3. Genetics of pre-eclampsia 
There is a wide spectrum of plausible evidence 
that the cause of pre-eclampsia is at least partly 
genetic, and the underlying patterns of its herita-
ble aspects have been intensively studied (Rob-
erts and Cooper. 2001). A familial predisposition 
to pre-eclampsia has been confirmed in a num-
ber of studies which have observed a 2–5 -fold 
increase in the risk of the disease among first-
degree relatives to women with pre-eclampsia 
(Chappell and Morgan. 2006). 
There is no universally accepted susceptibil-
ity gene for pre-eclampsia, but genome-wide 
linkage analyses of the affected families have 
yielded three loci with significant linkage and 
many additional loci that could be associated 
with pre-eclampsia to a minor extend (Chappell 
and Morgan. 2006). The three main loci have 
been identified in chromosomes 2p12, 2p25 and 
9p13 (Arngrimsson et al. 1999, Laivuori et al. 
2003). 
Studies on more than 50 candidate genes, 
many of which have been suggested on the basis 
of the typical pathophysiological features of the 
established disease, have been reported, but only 
eight of them seem to account for about 70% of 
the publications concerning this matter (Chap-
pell and Morgan. 2006). Furthermore, the re-
sults of these candidate gene studies are both 
conflicting and inconclusive. However, by com-
bining data from the genetic studies it has been 
estimated that the genetic factors contribute to 
more than half of the risk of pre-eclampsia. 
3.1.4. Prevention and treatment of pre-eclampsia 
As the etiology of pre-eclampsia remains unclear, 
the only truly effective primary prevention 
method would be contraception (Dekker and 
Sibai. 2001, Briceno-Perez et al. 2009). However, 
manipulation of some of the known risk factors 
of pre-eclampsia can, be used as potential pri-
mary preventive strategies, at least theoretically. 
Such factors include, for instance, limited sperm 
exposure, paternal-dependent risk factors, 
obesity and insulin resistance. 
Trials on secondary prevention, meaning 
break-off the disease process before its clinical 
manifestation, have been based on the known 
pathophysiological mechanisms of pre-
eclampsia, mainly focusing on specific drugs 
(aspirin and other antiplatelet agents, progester-
one, nitric oxide), nutritional supplies or dietary 
restrictions (calcium, antioxidants, fish oil, low 
dietary salt, folic acid, garlic, protein and energy 
supplementation or restrictions) and lifestyle 
choices (rest, exercise etc.) (Dekker and Sibai. 
2001, Briceno-Perez et al. 2009). However, 
based on the latest Cochrane database systematic 
review and other meta-analyses, antiplatelet 
agents, largely low-dose aspirin, have only mod-
erate benefits in prevention of pre-eclampsia, 
preterm birth, and adverse effect of them in fetal 
growth (Duley et al. 2007, Askie et al. 2007) as 
the risk of pre-eclampsia is lowered by 10-14%. 
The benefits of calcium supplementation have 
been observed only among mothers with high 
risk of pre-eclampsia or low dietary calcium in-
take (Dekker and Sibai. 2001, Briceno-Perez et 
al. 2009), although in them, calcium supplemen-
tation seems to halve the risk of the syndrome 
(Hofmeyr et al. 2010). Of the other methods or 
agents tested for secondary prevention of pre-
eclampsia, there has been not enough evidence, 
or it has been insufficient in quality, to draw 
positive conclusions (Briceno-Perez et al. 2009). 
By far the most common interventions con-
sidering pre-eclampsia have been associated with 
tertiary prevention. This refers to various kinds 
of attempts to lower the risk of complications 
caused by the disease, thus, being somewhat 
synonymous to “treatment” (Dekker and Sibai. 
2001). The scope in the antenatal care of pre-
eclampsia is to prolong the pregnancy, maximiz-
ing fetal viability, and to protect the mother from 
the adverse effects of the manifestations of the 
syndrome, most commonly hypertension (Datta. 
2004). In fact, antihypertensive agents are the 
most commonly used medication in manifest 
pre-eclampsia (Datta. 2004). They protect the 
mother from the potential adverse effects of un-
controlled hypertension, especially intracerebral 
hemorrhage (Datta. 2004, Steegers et al. 2010). 
In addition, intravenous MgSO4 can be used for 
both prevention and management of eclamptic 
convulsions (Datta. 2004, Steegers et al. 2010). 
Despite of many pharmacological advantages, 
timed delivery still remains of special importance 
in the tertiary prevention of pre-eclampsia 
(Datta. 2004, Steegers et al. 2010, Briceno-Perez 
et al. 2009). 
 21 
3.2. Mechanisms of pre-eclampsia 
The etiology of pre-eclampsia has been inten-
sively searched, but a final explanation remains 
to be stated. Although commonly accepted as a 
key step in the pathogenesis of pre-eclampsia, 
the placental origin as a definitive cause of the 
disease has been challenged by several theories 
seeking for the underlying sources for the placen-
tal failure. Some observations have been sug-
gested that mainly genetic factors (both fetal and 
maternal genes) would determine the risk of pre-
eclampsia whereas environmental factors have 
been suggested to mainly interact with the ge-
netic ones, determining the predisposition and 
severity of the disease (Datta. 2004, Chappell 
and Morgan. 2006). Interestingly, pre-eclampsia 
has been observed to be namely a disorder of the 
nullipara (Makkonen et al. 2000), supporting the 
theory of immune maladaptation as the main 
mediator of its pathogenesis (Dekker and Robil-
lard. 2007). Recently, many of the studies on the 
pathogenesis of pre-eclampsia have focused on 
the angiogenic imbalance, which has been found 
as one of the leading disturbances in the placen-
tal level, possibly due to abnormal, initial placen-
tation. 
3.2.1. Placental vascular remodeling  
Pre-eclampsia has been observed to take place 
only in the presence of the placenta. The patho-
physiology of the disease has been characterized 
as placental hypoperfusion and ischemia, begin-
ning from the implantation and early pregnancy.  
The most typical morphological changes noted in 
the uteroplacental vasculature of pre-eclamptic 
women is the impaired vascular remodeling of 
the spiral arteries, caused by abnormal tro-
phoblast invasion and taking place toward the 
end of the first trimester (Figure 2, next page ). 
In pre-eclampsia, this process has been observed 
rudimentary leading to a cascade of its character-
istic pathophysiological events (Brosens et al. 
1972). 
In pre-eclampsia, the cytotrophoblasts fail to 
mimic a vascular adhesion phenotype (Zhou et 
al. 1997a) and their invasion is shallow, limited 
to the superficial layer of the decidua (Figure 2.). 
They fail to transform the maternal spiral arter-
ies to high-caliber capacitance vessels, and they 
remain small-caliber resistance vessels. Conse-
quently, the placental morphology is character-
ized as narrow myometrial arteries and minimal 
arteriovenous shunts in women with subsequent 
pre-eclampsia. These placental vessels are unable 
to provide adequate perfusion considering the 
demands of the growing fetus. Consequently, the 
failed trophoblast invasion and the impaired 
vascular remodeling lead to hypoperfusion of the 
placenta (Brosens et al. 1972). 
Figure 2. ( Next page ). In normal pregnancy, the remodeling of the maternal spiral arteries is caused by the “endo-
vascular” cytotrophoblast cells, which invade the narrow, highly coiled, musculo-elastic spiral arteries of the decidua, 
until the inner third of the myometrium (top). As a result, the maternal spiral arteries are widened to form high-caliber 
low-resistance channels, which are no longer responsive to vasomotor influences. During the invasion, this specific 
population of trophoblasts transforms into endothelial phenotype cells, which replace the maternal endothelium of the 
spiral arteries in a process called “pseudovasculogenesis”. 
The abnormal trophoblast invasion and the following impaired vascular remodeling of the maternal spiral arteries are 
characteristic of pre-eclampsia (bottom). The cytotrophoblasts fail to mimic a vascular adhesion phenotype resulting in 
shallow invasion and failure in the transformation of the maternal spiral arteries into high-caliber capacitance vessels 
instead of small-caliber resistance vessels. Consequently, the placental morphology is characterized as narrow myome-
trial arteries and minimal arteriovenous shunts in women designated to develop pre-eclampsia. 
The impaired vascular remodeling lead to placental hypoperfusion and following disturbances in providing adequate 
perfusion for demand of the growing fetus. Furthermore, the insufficient placentation has been suggested to lead to a 
cascade of typical pathophysiological events known as the maternal disease of pre-eclampsia. 
   
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Figure 2. The impaired trophoblast invasion and remodeling of the spiral arteries in 
the pathophysiology of pre-eclampsia. 
Copyright© 2011 Hannu Koponen. All rights reserved. 
 
3.2.2. Maternal endothelial dysfunction 
The failure in remodeling the placental bed in 
early pregnancy and the subsequent placental 
ischemia has been suggested to lead to genera-
tion releases some vasoactive substances into the 
maternal circulation which further act on mater-
nal endothelium (Roberts et al. 1989, de Groot 
and Taylor. 1993). This has been postulated to 
result in an endothelial cell disorder throughout 
the vasculature and lead to the multi-organ fail-
ure, which can be detected in pre-eclampsia 
(Roberts et al. 1989, de Groot and Taylor. 1993). 
This vascular endothelium is considered as the 
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target organ of the placental pathophysiological 
changes in the disease.  
The most important endothelial cell func-
tions associated with pre-eclampsia are increased 
vascular tone, lipid uptake, intravascular coagu-
lation, vascular permeability, and inadequate 
immunological response (de Groot and Taylor. 
1993). The clinical symptoms of pre-eclampsia 
reflect these malfunctions of the maternal endo-
thelial cells (Roberts et al. 1989, de Groot and 
Taylor. 1993). Most often the endothelial cell 
dysfunction is described as a cascade of coagula-
tion, vasoconstriction and intravascular fluid 
redistribution, together of which manifest as the 
clinical syndrome of pre-eclampsia finally lead-
ing to vasoconstriction and end-organ ischemia 
(Roberts et al. 1989).  
3.2.3. Hemodynamic changes 
Arterial blood pressure and peripheral vascular 
resistance decrease during normal pregnancy. 
However, because of the overt vasoconstriction 
associated with the clinical symptoms of pre-
eclampsia, the systemic vascular resistance re-
mains higher whereas the cardiac output stays 
lower in women with this pregnancy compli-
cation (Datta. 2004).  Women with subsequent 
pre-eclampsia represent altered vasorelaxation 
independent of the endothelium (Khan et al. 
2005). Furthermore, there is a slight increase in 
the blood pressure preceding the onset of the 
manifest symptoms of the disease. 
3.2.4. Edematous changes in kidney and brain 
Pre-eclampsia and eclampsia are associated with 
a global hypoperfusion of organs. Disordered 
maternal endothelium is abundant in the kidney, 
representing one of the main characteristic 
pathologic steps of pre-eclampsia:  glomerular 
endotheliosis. 
Eclampsia is often characterized as cerebral 
edema and intracerebral parenchymal hemor-
rhage. The cerebral edema, however, is inde-
pendent of the severity of hypertension, and 
instead of being caused by the blood pressure 
elevation it has been suggested to result from the 
endothelial dysfunction (Zeeman. 2009). 
3.3. Prediction of pre-eclampsia 
Despite of decades of attempts to identify the 
women “at risk” of pre-eclampsia, it remains a 
critical aim for research. Many potential tests 
have been assessed for their ability to detect the 
women at risk of pre-eclampsia already during 
the early pregnancy. These setting have com-
monly assessed placental perfusion or vascular 
resistance, and serum or urine markers of pla-
cental distress, renal and endothelial dysfunc-
tion, oxidative stress, and insulin resistance. 
Other measured compounds have been fetal or 
placental –derived products and hormones 
(Steegers et al. 2010, Carty et al. 2008). A subset 
of angiogenic factors has recently been under 
extensive research as potential contributor to the 
pathogenesis and thereby offering a predictive 
tool for subsequent pre-eclampsia.  
Only a few of the nearly 30 tests evaluated in 
one of the lately published reviews reached speci-
ficity above 90% (Meads et al. 2008). No single 
test, however, met the clinical standards for a 
predictive test, which was concluded also by 
authors of another systematic review (Conde-
Agudelo et al. 2004). Although new maternal 
circulating candidates, such as soluble endoglin, 
activin-A, inhibin-A, pregnancy-associated 
plasma protein-A (PAPP-A), and placental pro-
tein 13 (PP13), have been introduced for poten-
tial screening purposes, it has become obvious 
that a single biomarker is unlikely to predict all 
forms of such a multifactorial syndrome as pre-
eclampsia (Thangaratinam et al. 2008).  
Recently, it has been proposed that a combi-
nation of tests, such as ultrasound screening 
(uterine artery Doppler waveforms, placental 
thickness and homogeneity) and analyses of 
circulating markers associated with placental 
insufficiency would increase the utility of former 
assessments (Steegers et al. 2010). As an exam-
ple, a logistic regression analysis combining uter-
ine artery pulsatility index, mean arterial pres-
sure, serum PAPP-A, serum placental growth 
factor (PlGF), body-mass index (BMI), and the 
presence of nulliparity or previous pre-eclampsia 
has been observed to have high sensitivity and 
specificity in prediction of early onset pre-
eclampsia (Steegers et al. 2010). In addition, 
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ratios of factors associated with the possible 
underlying angiogenic imbalance in pre-
eclampsia distinguish between the women with 
subsequent disease later in pregnancy (Steegers 
et al. 2010, Carty et al. 2008).  
3.4. Intrauterine growth retardation 
(IUGR) 
Adequate fetal growth is dependent of four prin-
cipal determinants. First, each fetus has a unique 
genetic growth potential associated with parental 
genetic properties. The respective growth poten-
tial is later modified by the placental function as 
well as maternal and fetal health. If all of the last 
three variables are unaffected during the preg-
nancy, the fetus will achieve the genetically de-
termined growth potential. 
3.4.1. Classification of disturbances in fetal 
growth 
The term “small for gestational age” (SGA) refers 
to a small infant, failed to achieve a gender-
specific weight threshold, most often defined as 
the 10th percentile of the referred population 
(Bamberg and Kalache. 2004). However, this 
definition will lead to the fact that about 10% of 
healthy population is classified as SGA. To avoid 
over-treatment, it is important to distinguish 
between the small but healthy fetuses and the 
ones with compromised fetal growth. Therefore, 
customized fetal weight centiles have been stud-
ied as a more precise tool for assessing potential 
growth disturbances in utero (Gardosi. 2009).  
Importantly, different from the population-
based SGA fetuses, a real compromise in fetal 
growth should be diagnosed with intrauterine 
growth retardation (IUGR). In this subgroup, the 
neonates fail to achieve the growth potential they 
were assumed according to the principals above 
(Baschat. 2004). These infants are usually also 
SGA, but not as a rule (Bamberg and Kalache. 
2004). 
In developing countries, the valid informa-
tion of the duration of gestation is often impossi-
ble to obtain, and the incidence of low birth-
weight (LBW) is often used as a proxy to repre-
sent the occurrence of IUGR. Worldwide, almost 
16% of newborns were classified as LBW infants 
during 1997–2001 (UNICEF. 2004). However, 
up to 96% of them are born in developing coun-
tries where the incidence of LBW has been esti-
mated to be 2.5 times that of industrialized coun-
tries (UNICEF. 2004). 
In Finland, SGA infants accounted for 2.0% 
of the infants born after singleton pregnancies 
during 2007–2008 (Vuori and Gissler. 2010). At 
this time period, the percentage of LBW infants 
(< 2501 g) was 3.2% in singleton and 4.4% in all 
pregnancies with representative percentages for 
preterm births of 4.5% and 5.7%. The occurrence 
of very low birthweight (VLBW; < 1501 g) new-
borns was 0.9% including also twins and triplets. 
Perinatal mortality in Finland has long been one 
of the lowest in the world, being 5.0 per 1000 
children (Vuori and Gissler. 2010). 
3.4.2. Diagnosis and risk factors of IUGR 
Detection of the possible disturbances in fetal 
growth is essential, as it may improve the ante-
natal outcome of the fetus that is at risk of com-
plications from the growth retardation. The main 
approach is to separate IUGR resulting from 
placental disease from fetuses with underlying 
etiologies or those constitutionally small ones. 
Thus, the Doppler investigation of fetoplacental 
blood flow accompanied with the ultrasound 
assessment of amniotic fluid volume and fetal 
anatomy and growth play a central role in the 
diagnosis (Baschat. 2004). 
Growth retardation implies that fetal growth 
is compromised by factors originating in the 
mother and her environment, the placenta or the 
fetus. Besides fetal chromosomal and structural 
abnormalities, impaired placental vascular de-
velopment accounts for most of IUGR diagnoses 
in otherwise healthy, singleton pregnancies in 
the Western world (Baschat. 2004, Grivell et al. 
2009).  
Logically, IUGR is associated with increased 
perinatal mortality and morbidity. Furthermore, 
there might also be an increased risk of health 
problems in the adulthood of the offspring, such 
as type-2 diabetes, cardiovascular disease and 
metabolic syndrome (Barker. 2002). 
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3.4.3. Pathophysiology of IUGR and possible 
association with pre-eclampsia 
Especially when starting early in gestation and 
not being secondary to any other pregnancy 
complication, IUGR has been suggested to be a 
form of pre-eclampsia affecting only the myo-
metrium, placenta, and the fetus, although not 
causing any systemic effects on the maternal 
endothelium (Regnault et al. 2002). The hy-
pothesis has been based on the findings on simi-
lar vascular defects: poor vascularization of pla-
cental bed spiral arteries has been detected in 
both of the conditions (Khong et al. 1986). 
Therefore, they have been postulated to share a 
common etiology associated with vascular de-
fects (Regnault et al. 2002, VanWijk et al. 2000, 
Myatt. 2002). It also appears likely that factors 
regulating vascularization and angiogenesis in 
early placenta play a role in the pathophysiology 
of these diseases. 
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4. Smoking during pregnancy 
4.1. Smoking during pregnancy 
Smoking among pregnant women is associated 
with a number of adverse fetal and obstetrical 
complications (Higgins. 2002). These comprise 
placenta previa, placental abruption, premature 
rupture of the membranes, preterm birth, IUGR 
and sudden infant death syndrome (SIDS; Hig-
gins. 2002, Andres and Day. 2000). Cigarette 
smoking during pregnancy is a major risk for 
pregnancy-related morbidity and mortality 
worldwide (Higgins. 2002, Andres and Day. 
2000).   
In Finland, the smoking rate during preg-
nancy in 1997 was counted amongst 15% of preg-
nant women (Jaakkola et al. 2001). Smoking was 
defined as cigarette smoking daily or occasionally 
at some point during pregnancy. The information 
retrieved from a questionnaire was highly com-
parable to that of the medical records and the 
Finnish Medical Birth Registry data on smoking 
during pregnancy. The prevalence of smoking 
during pregnancy in Finland in this study was 
similar to that observed ten years earlier, in 1987 
(Jaakkola et al. 2001). According to the Finnish 
Medical Registry data, there had been no change 
in the percentage of children exposed to mater-
nal smoking in utero during the next decade as 
its incidence was still 14.7% in 2008, and slightly 
higher (17.5%) when counting only the infants of 
primiparas (Vuori and Gissler. 2010). However, 
30% of the mothers quit smoking after the first 
trimester in the same year. In the western coun-
tries, it has been approximated that about        
10–20% of all women smoke during pregnancy 
(Andres and Day. 2000, Ananth and Cnattingius. 
2007). 
The adverse effects of smoking on pregnancy 
have been suggested to be produced mostly by 
nicotine, but also by the other numerous toxins 
detected in cigarette smoke, e.g. carbon monox-
ide, lead, selenium and cadmium (Leonardi-Bee 
et al. 2008, Pulkkinen. 1989). Fetal and neonatal 
nicotine exposure alone leads to major adverse 
postnatal health consequences (Bruin et al. 
2010).   
A list of the fetoplacental consequences of 
maternal smoking in early and late pregnancy is 
shown in Table 4. (Jauniaux and Burton. 2007). 
 
 
Table 4. Placental and fetal effects of maternal smoking in early and late pregnancy. 
The list has been modified after Jauniaux et al. (2007). 
Early pregnancy 
 
 
 
Miscarriage 
Ectopic pregnancy 
Placenta previa and placenta previa-accreta 
Fetal orofacial clefts 
Late pregnancy 
 
 
 
 
Intrauterine growth retardation 
Placental insufficiency 
Placental abruption 
Premature rupture of the placental membranes 
Preterm delivery 
Perinatal death 
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4.2. Vascular effects of nicotine 
exposure 
Exposure to cigarette smoke in utero is associ-
ated with later hypertension also in humans (Be-
ratis et al. 1996, Blake et al. 2000). Based on 
animal studies, this phenomenon is likely to be 
mediated by nicotine (Gao et al. 2008). In rats, 
fetal and neonatal exposure to nicotine also 
causes increases in postnatal blood pressure due 
to endothelial dysfunction (Xiao et al. 2007) 
and/or changes in renal structure or function 
(Mao et al. 2009, Pausova et al. 2003). Admini-
stration of high doses of nicotine to animals dur-
ing pregnancy has adverse consequences on both 
the maternal and fetal cardiovascular such as 
subsequent type II diabetes, obesity, hyperten-
sion and respiratory dysfunction (Bruin et al. 
2010). 
4.3. Placental effects of smoking 
Nicotine can travel across the placenta, after 
which it accumulates in the amniotic fluid and 
the fetal blood. Also cotinine, the main metabo-
lite of nicotine crosses the placenta (Pastrakuljic 
et al. 1998). Thus, the fetuses of smoking 
mothers are exposed to even relatively higher 
cotinine concentrations as compared to their 
mothers, and there is a positive correlation be-
tween maternal serum cotinine concentrations 
and those in fetal serum and amniotic fluid 
throughout pregnancy (Jauniaux et al. 1999). 
Cadmium, Cd, is a common environmental 
pollutant, which is also present with high 
amounts in tobacco smoke. It has been observed 
to cause serious disturbances in human repro-
ductive functions. During pregnancy, Cd is trans-
ferred to the fetus through the placenta, although 
it also accumulates in the placenta probably pre-
venting the fetus from the toxic effects of the 
metal (Pulkkinen. 1989, Jauniaux et al. 1999). 
Smoking results in many placental morpho-
logical changes related to the villous cytotropho-
blast proliferation and differentiation (Genbacev 
et al. 1995, Genbacev et al. 2000, Genbacev et al. 
2003) as well as the placental vasculature (Pfar-
rer et al. 1999, Zdravkovic et al. 2005).  Some of 
the placental defects may result in reduction of 
the placental vascularization already in earlier 
stages of pregnancy. These morphological chan-
ges begin to develop in early pregnancy resulting 
in alterations in the biological functions of both 
the trophoblastic and fetal cells, mainly associ-
ated with synthetic (protein metabolism) and 
enzymatic activity (reviewed in Zdravkovic et al. 
2005). 
The dysregulation of the placental blood ves-
sels in connection to maternal smoking has been 
assumed to be due to some compensatory 
mechanisms in the placental blood flow (Pfarrer 
et al. 1999, Zdravkovic et al. 2005). The relative 
volumes of maternal intervillous space and sur-
face area of fetal capillaries are increased 
whereas both the relative and absolute volumes 
of the fetal capillaries are reduced, which is sug-
gested to happen as a result of a decrease in 
mean capillary diameter rather than total length 
(Bush et al. 2000).  
Interestingly, the alterations seen in smok-
ing women are in contrast to the main adaptive 
changes associated with pregnancies with pre-
placental hypoxia, suggesting that the fetoplacen-
tal unit might be affected by some other factors 
connected to cigarette smoke. A modified list of 
the placental morphological changes associated 
with maternal smoking is shown in Table 5.  
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Table 5. Placental morphological changes associated with maternal smoking.  
The table has been modified after Jauniaux and Burton (2007). 
Increased Trophoblastic and villous membrane thickness 
Thickness of the trophoblast basal membrane 
Necrosis of the syncytiotrophoblast 
Apoptosis in the syncytiotrophoblast 
Expression of pVHL, HIF, and VEGF 
Simulation of nicotinic acetylcholine receptors 
Vasoconstrictive response to endothelin-1 
Decreased Decrease in villous capillary volume fraction 
Decrease in total surfaces of syncytial knots 
Progesterone synthesis 
pVHL = von Hippel-Lindau tumor suppressor protein      HIF = hypoxia-inducible transcription factor 
VEGF = vascular endothelial growth factor 
 
4.4. Effects of smoking on perinatal 
outcome  
Smoking has been referred to as the cause of 
about 15% of all preterm births and 20–30% of 
all infants born with a low birthweight, which are 
associated with increased risk of neonatal mor-
bidity and mortality (reviewed by Andres and 
Day. 2000). Indeed, maternal tobacco use has 
been suggested to increase the overall perinatal 
mortality by 150%. 
The direct effect of the cigarette smoke tox-
ins on fetal cell proliferation and differentiation 
could explain the increased risk of miscarriage, 
IUGR, stillbirth, preterm birth and placental 
abruption reported by epidemiological studies 
(Higgins. 2002, Andres and Day. 2000). In the 
newborn, maternal smoking has been noted to 
associate with a decrease in birthweight, new-
born fat mass, and changes in protein metabo-
lism and enzyme. 
4.5. Smoking and pre-eclampsia 
In a systematic review of 28 cohort studies con-
sidering the association between cigarette smok-
ing during pregnancy and pre-eclampsia, each 
study reported a negative connection between 
the incidence of pre-eclampsia and cigarette 
smoking during pregnancy (Conde-Agudelo and 
Belizan. 2000). 
In a recent study on certain high-risk groups, 
smoking was associated with changes in the con-
centrations of pro-angiogenic factors during 
early pregnancy, but no obvious association with 
subsequent pre-eclampsia was observed (Jeya-
balan et al. 2008). A more detailed review of the 
angiogenic factors in connection to smoking is 
given in Chapter 5 and the risk factors of pre-
eclampsia are reviewed in Chapter 3. 
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5. Vascular endothelial growth factor (VEGF) family and 
soluble VEGF receptor-1 
The human VEGF gene family comprises VEGF-
A (usually referred to as VEGF), VEGF-B, VEGF-
C, VEGF-D, and placental growth factor (PlGF). 
Besides them, alternative non-mammalian ho-
mologs of VEGF, often referred to as viral VEGF 
(VEGF-E) and snake venom VEGF (VEGF-F), 
have been identified (Lyttle et al. 1994, Takaha-
shi et al. 2004). All of the VEGFs above are di-
meric glycoproteins. Each of the VEGF family 
members contains of a central VEGF homology 
domain (VHD) consisting of 92–96 amino acids 
(Yamazaki et al. 2009). They share 29–64% of 
their VHD regions, but the eight cysteine resi-
dues of the VHD can be seen in all members and 
they are highly conserved. Besides of the central 
VHD, each molecule has N and C              –
terminal extensions (Yamazaki et al. 2009). 
Each of the VEGF family members binds, in 
unique ligand-specific manner, to some of the 
three tyrosine kinase receptors (RTK), known as 
the VEGF receptors.  VEGFR-1 (also referred as 
fms –like tyrosine kinase-1, Flt-1), VEGFR-2 
(kinase insert domain receptor, KDR), and 
VEGFR-3 (Flt-4). Of these endothelial cell mem-
brane receptors, VEGFR-1 and -2 are usually 
distributed on vascular endothelial cells mediat-
ing a number of angiogenic signals, such as en-
dothelial cell proliferation and migration. In 
contrast, VEGFR-3 is mainly expressed on the 
lymphatic endothelium taking part in lymphan-
giogenesis (Shibuya et al. 1999).  
5.1. VEGF-A 
VEGF is known as a central angiogenic molecule 
during development, adult physiology and pa-
thology (Ferrara et al. 2003). It was earlier 
known as the vascular permeability factor (VPF) 
identified in 1983 in the supernatant of a quinea-
pig tumor cell line by Senger and colleagues (re-
viewed in Ferrara 2009: History of Discovery). 
However, attempts to purify or sequence the 
protein were not successful.  
Six years later, in 1989, Napoleone Ferrara 
isolated and identified a novel endothelial cell 
mitogen from medium conditioned by bovine 
pituitary follicular cells. He had begun the effort 
as a postdoctoral fellow in the early 1980s. Since 
this newly found protein displayed growth-
promoting activity only on vascular endothelium, 
it was named as “vascular endothelial growth 
factor” (Ferrara and Henzel. 1989).  
Ferrara and his colleagues continued their 
intensive research on VEGF, and soon, they iso-
lated clones of the first three VEGF isoforms 
(Leung et al. 1989). Concomitantly, the earlier 
work on VPF had been followed up by another 
group of scientists, led by Daniel Connolly. They 
had finally advanced in further analyses on VPF, 
ending up in the cloning of the protein. For their 
great surprise, the human clone of VPF, de-
scribed by the Connolly’s team, encoded a pro-
tein identical to VEGF189. 
5.1.1. Structure 
The best known subtype of VEGF-A, VEGF165, 
from here on referred to as VEGF, is a secreted, 
homodimeric, heparin-binding and glycosylated 
protein, and it is about 46 kDa of its molecular 
size (Ferrara et al. 2003). Due to alternative exon 
splicing, at least eight other VEGF isoforms vary-
ing by the number of amino acids have so far 
been identified: VEGF121, VEGF145, VEGF148, 
VEGF162, VEGF165b, VEGF183, VEGF189 and 
VEGF206 (reviewed in Takahashi and Shibuya. 
2005).  Of these VEGF subtypes, VEGF121, 
VEGF165 and VEGF189 are the predominant ones, 
and they can be secreted by most cell types 
(Robinson and Stringer. 2001).  
VEGF165b, is a unique form of VEGF acting 
in an inhibitory fashion: it binds to VEGFR-2 
with the affinity of VEGF165 without resulting in 
the activation of the receptor and the subsequent 
downstream signaling cascade (Woolard et al. 
2004). Different biological functions of VEGF 
isoforms have been detected in studies on iso-
form-specific VEGF knockout mice concluding 
that VEGF165 is the main mediator of the actions 
of VEGF (reviewed in Ferrara. 2004). 
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5.1.2. Function 
VEGF is known for its two main biological func-
tions: First, it is able to stimulate vascular endo-
thelial cell proliferation. It enhances mitogenesis 
and angiogenesis of the endothelial cells (Fer-
rara. 2004). Second, it has a capacity to increase 
vascular permeability. Indeed, VEGF was origi-
nally described as a permeability factor (Ferrara 
et al. 2003), and it was later described to cause 
vasodilatation inducing the endothelial nitric 
oxide synthase (eNOS) leading to an increase in 
nitric oxide production (Fukumura et al. 1997).  
Besides the two main features above, VEGF acts 
as a survival factor for the endothelium during 
both physiological and pathological angiogenesis.  
VEGF is essential for embryonic develop-
ment as homozygous VEGF knockout mice die at 
embryonic day E8–E9 due to failure in blood 
island formation, defects in vascular formation 
and disturbances in endothelial cell development 
(reviewed in Ferrara. 2004). Also the concentra-
tions of VEGF during early development seem to 
be critical: even the lack of a single VEGF allele 
causes death of the mice in utero by E12.5 repre-
senting serious disturbances in the vascular sys-
tem (reviewed in Ferrara. 2004).  
5.1.3. Sites of expression 
Vascular endothelial growth factor is expressed 
by various adult and fetal tissues as well as by 
various cultured cell types (Maharaj et al. 2006). 
Besides of these normal tissues, it is widely ex-
pressed in tumors (Hicklin and Ellis. 2005). 
During organogenesis, VEGF plays an essential 
role in the development in the formation of the 
cardiovascular system (Haigh. 2008). VEGF can 
be detected in fetal circulation at the delivery and 
in neonatal venous blood at least during the first 
postnatal days.  
Throughout human life, VEGF is a major 
mediator of angiogenic signals. However, angio-
genesis is restricted to certain physiological 
processes during adulthood. Thus, the expres-
sion pattern of VEGF is greatly altered in connec-
tion with these individual angiogenic events. In 
human 
 
 
physiology, VEGF is important especially during 
the female reproductive cycle in the uterus, ovary 
and breast, and in skeletal muscle response to 
exercise. The expression of VEGF is also up-
regulated in relation to the angiogenic actions in 
wound healing and bone repair. (Maharaj et al. 
2006) 
In female reproduction, increased VEGF 
production has been associated with endometri-
osis (McLaren et al. 1996), ovarian hyperstimula-
tion syndrome (Levin et al. 1998), and in patients 
with hydatidiform mole (Nomura et al. 1998). Of 
the numerous malignant tumors, which have 
been observed to express high amounts of VEGF, 
many are located in the female reproductive 
tract. For example, they include tumors of the 
ovary, endometrium, uterine cervix and the 
breasts (Doldi et al. 1996, Guidi et al. 1995, Guidi 
et al. 1997). 
5.1.4. Regulation of expression 
Hypoxia rapidly and reversibly up-regulates the 
gene expression of VEGF both in vitro and in 
vivo (reviewed in Takahashi and Shibuya. 2005, 
Ferrara. 2004). This up-regulation is mediated 
by hypoxia-inducible factor-1 (HIF-1), which is a 
transcriptional activator including two subunits, 
HIF-1α and HIF-1β (Semenza. 2002). 
The expression of VEGF can also be in-
creased by some other growth factors or nitric 
oxide (NO), which regulate the release of VEGF 
in a paracrine or autocrine fashion in response to 
local hypoxia (Ferrara. 2004). Transforming 
events, such as oncogenic mutation and existence 
of tumor promoters have also been shown to 
result in induction of VEGF up-regulation (Fer-
rara. 2004). Besides them, a variety of hormonal 
substances have been shown to induce VEGF 
expression in different contexts (reviewed in 
Ferrara. 2004). These hormones comprise, for 
example, the thyroid-stimulating hormone 
(TSH), adrenocorticotropic hormone (ACTH), 
sex steroids (estradiol and progestins), and the 
gonadotropins e.g. follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), and  human 
chorionic gonadotropin (hCG). 
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5.2. PlGF 
Placental growth factor, a dimeric 46 kDa protein 
structurally closely related to VEGF, was identi-
fied 20 years ago (Maglione et al. 1991). PlGF-/- 
knockout mice are born without an apparent 
phenotype. Thus, it was first suggested that the 
loss of PlGF gene would not affect development, 
reproduction or the postnatal life. However, fur-
ther studies have shown that under pathologic 
conditions, such as ischemia, these mice have 
major impairment in their ability to respond to 
the ischemic damage through angiogenesis and 
adaptive arteriogenesis. Thus, PlGF is now con-
sidered mainly arteriogenic of its properties (re-
viewed in Ribatti. 2008). 
Following the alternative mRNA splicing of 
the primary transcript, four subtypes of human 
PlGF have been detected: PlGF131, PlGF152, 
PlGF203, and PlGF224, also referred to as PlGF -1, 
PlGF-2, PlGF-3 and PlGF-4, varying in terms of 
the number of amino acids, their secretion prop-
erties and their binding affinities.  
PlGF-1 is considered as the main form of the 
protein. It mediates its activity via VEGF recep-
tor-1 (see below), and unlike the other isoforms, 
it does not bind to heparan sulfate proteoglycans 
(HSPG) or the neuropilins (reviewed in Ribatti. 
2008). PlGF contributes to angiogenesis by dif-
ferent mechanisms: First, acting directly on the 
endothelial cells via VEGFR-1, it can drive VEGF 
to bind and activate VEGFR-2 and stimulate the 
VEGF sensitivity of the cell. Second, PlGF takes 
part in angiogenesis as it recruits mono-
cytes/macrophages, which play an important 
role in vessel growth, and it mobilizes hema-
topoietic progenitor cells from the bone marrow 
(reviewed in Ribatti. 2008). 
PlGF gene is highly expressed at all stages of 
pregnancy, although the amount of PlGF in-
creases toward the terminal development of the 
placenta (Khaliq et al. 1996, Persico et al. 1999). 
Both PlGF protein and mRNA have been ob-
served in the trophoblastic bilayer as well as in 
the villous mesenchyme. Although first found in 
the placental tissue, PlGF mRNA has later been 
detected in a number of other organs including 
the heart, lung, skeletal muscle, thyroid and adi-
pose tissue (Persico et al. 1999, Voros et al. 
2005).   
5.3. Other members of VEGF family  
5.3.1. VEGF-B 
Another member of the VEGF family, later 
named as VEGF-B because of its structural simi-
larities with VEGF, was characterized in 1996 by 
two independent research groups (Grimmond et 
al. 1996, Olofsson et al. 1996). VEGF-B is also 
produced in two different secreted sybtypes, 
resulting in a 21 kDa, non-glycosylated HSPG-
binding form (VEGF-B167), and a 32 kDa, O-
glycosylated and therefore freely diffusible form 
of the protein (VEGF-B186; Olofsson et al. 1996). 
Unlike VEGF, hypoxia does not seem to up-
regulate the expression of VEGF-B (Olofsson et 
al. 1996, Lagercrantz et al. 1996).  
VEGF-B is abundant in highly metabolic or-
gans and tissues, such as the skeletal muscle, 
brown fat and the myocardium. VEGF-B medi-
ates its actions via VEGFR-1 (Olofsson et al. 
1998). However, there is no clear evidence for the 
mitogenicity of VEGF-B in vivo. It has been sug-
gested to have important non-vascular roles, 
perhaps in the survival of smooth muscle cells by 
inhibiting apoptosis and inducing adequate in-
flammatory responses (reviewed in Cao. 2009). 
5.3.2. VEGF-C 
Like the other members of this protein family, 
VEGF-C is a secreted and further proteolysed 
homodimeric glycoprotein, approximately 21 
kDa of its final size in the extracellular envi-
ronment (Joukov et al. 1996, reviewed in Tam-
mela et al. 2005). VEGF-C binds to VEGF recep-
tor-2 and -3 (Joukov et al. 1996, Lee et al. 1996). 
Of the members of VEGF family, VEGF-C 
and VEGF-D are best known for their ability to 
induce growth of the lymphatic vasculature in 
mice. However, to some extend they are also 
mitogenic for vascular endothelial cells during 
embryonic development (Tammela et al. 2005, 
Enholm et al. 1998, Enholm et al. 1998, Jeltsch et 
al. 1997, Joukov et al. 1998). Like VEGF-B, the 
expression of VEGF-C is unaffected by hypoxia 
(Enholm et al. 1998).  
VEGF-C has been detected in various human 
tissues, including prolactin-secreting cells in the 
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anterior pituitary, heart, vascular smooth muscle 
cells, small intestine and thyroid gland, ovary, 
and placenta (Joukov et al. 1996, Partanen and 
Paavonen. 2001, Gu et al. 2006). In the placenta, 
VEGF-C has been detected in villous core endo-
thelium as well as in invasive cytotrophoblasts 
during early gestation, but not at term (Gu et al. 
2006, Zhou et al. 2002).  
5.3.3. VEGF-D 
VEGF-D was first isolated as a fibroblast growth 
factor (FGF), but was then noticed to have highly 
similar structural properties as the VEGF family 
(Orlandini et al. 1996, Yamada et al. 1997). It has 
many common features with VEGF-C as it also 
binds to VEGFR-2 and VEGFR-3, and they also 
share many details in their expression pattern. 
VEGF-D is, indeed, strongly expressed in the 
heart, muscle and small intestine (Joukov et al. 
1996, Lee et al. 1996, Achen et al. 1998).  
VEGF-D is present in mice and human em-
bryonic lungs, thereby considered to be of special 
importance during vascularization of lung tissue 
at the last trimester of pregnancy (Tammela et al. 
2005, Farnebo et al. 1999). In humans, VEGF-D 
can be detected in vascular smooth muscle cells, 
lungs, heart, small intestine, skeletal muscles, the 
innermost zone of adrenal cortex, and serotonin-
positive enteroendocrine cells later, in the adult-
hood (Yamada et al. 1997). In the placenta, 
VEGF-D is localized in syncytiotrophoblasts and 
villous core endothelium (Gu et al. 2006). 
In human disease, the lymphangiogenic 
growth factors VEGF-C and VEGF-D, and their 
receptors, have been shown to be associated with 
lymphedema, Kaposi´s sarcoma, vascular tumors 
and tumor metastases (Jussila and Alitalo. 
2002). 
5.3.4. VEGF-E and VEGF-F 
VEGF homologues have also been found in the 
genomes of Orf viruses, which have been shown 
to have VEGF –like activities. VEGF-E refers to a 
group of these proteins, of which at least five 
have been described in the literature (reviewed 
by Joukov et al. 1998 and Shibuya. 2003). All 
forms of VEGF-E are able to selectively bind and 
activate VEGFR-2, which provides a unique tool 
for studies on the biological function of this spe-
cific subtype of the VEGF receptor (Shibuya. 
2003).  Furthermore, its affinity to VEGFR-2 is 
very high. 
As reviewed by Yamazaki et al. 2009, snake 
venom has been found as an exogenous source of 
unique VEGF –like protein, recently named as 
“VEGF-F” (Yamazaki et al. 2009). Two different 
forms of VEGF-F, Vammin and VR-1, were the 
first snake venom VEGFs to be found. They are 
homodimeric, heparin-binding proteins, similar 
to other VEGF subtypes, although with distinct 
biochemical properties. Vammin and VR-1 bind 
only VEGFR-2 with high affinity. However, two 
novel forms of VEGF-F have been shown to bind 
VEGFR-1, although preferring VEGFR-2. 
Of the snake venom VEGFs, at least Vammin 
and VR-1 have been noted to have hypotensive 
potential. Furthermore, they can induce vascular 
permeability, in which the response has been 
observed to be stronger than after stimulus en-
hanced by human VEGF.  Besides those longer 
known VEGF-Fs, Yamazaki et al. showed that the 
venom -type VEGFs are widely found in several 
viper venoms, and they are highly variable in 
structure and function among species (Yamazaki 
et al. 2009).  
5.4. VEGF –receptors 
The members of the VEGF family bind to one or 
two of the three VEGF receptors with different 
affinity and selectivity. For example, VEGF binds 
both VEGFR-1 and -2, although the latter one 
with a 10-fold affinity, whereas VEGF-B and 
PlGF are specific to VEGFR-1. Upon binding 
their ligands, the VEGFRs dimerize and become 
phosphorylated as a positive response to the 
stimulus (Shibuya et al. 1999). A schematic pres-
entation of the mammalian VEGF family, includ-
ing also the soluble receptors (introduced above), 
is shown in Figure 3.  
In addition to these receptor tyrosine kinase 
–type (RTK) receptors, some non-RTK –type 
receptors, neuropilin-1 (NRP-1) and heparan 
sulfate proteoglycans (HSPGs), have been found 
as co-receptors for VEGFs. Certain subtypes of 
VEGF, VEGF-B, and PlGF can also bind to   
NRP-1, NRP-2, or HSPG with their C-terminal 
regions, which results in modulation of the sig-
naling via the VEGFRs (Ferrara. 2004).  
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Figure 3. The VEGF family. 
Copyright© 2011 Hannu Koponen. All rights reserved. 
 
Figure 3. Schematic illustration of the mammalian VEGF family including the three cell membrane receptors named as 
VEGFR-1, VEGFR-2 and VEGFR-3, and their five ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF. The figure 
demostrates the unique binding profile of each one of the ligands for one or two of the cell membrane receptors. In addi-
tion, VEGFR-1 and VEGFR-2 are known to occur in a soluble form in vivo, e.g. in the human circulation. The figure also 
represents the physiological role of soluble VEGFR-1 (sVEGFR-1) in antagonizing VEGF-A, VEGF-B and PlGF. 
 
5.4.1. VEGFR-1 
VEGFR-1, a 180 kDa membrane-bound protein, 
was the first VEGF receptor to be described in 
1990 (de Vries et al. 1992). VEGFR-1 binds VEGF 
with high affinity but induces rather weak kinase 
activity (Shibuya. 2006). It also binds PlGF and 
VEGF-B, although with even weaker affinity than 
VEGF-A (Park et al. 1994, Sawano et al. 1996).  
Knockout models of VEGFR-1 have revealed 
that these null-mutant mice die due to over-
growth and disorganization of blood vessels at 
E8.5–9.5 (Fong et al. 1995). Thus, during em-
bryogenesis, it firstly acts as a negative regulator 
of angiogenesis by trapping free VEGF and 
thereby suppressing the accessibility of VEGF for 
its other receptor, VEGFR-2, on the endothelial 
cell surface (Shibuya. 2006). 
Secondly, during adulthood, VEGFR-1 medi-
ates paracrine signals on the endothelium. On 
the other hand, the VEGFR-1 on macrophages is 
likely to potentate the angiogenic actions medi-
ated by VEGFR-2. Furthermore, VEGFR-1 medi-
ates signals of vascular permeability with in-
flammation, and stimulates tumor growth and 
metastasis.  
VEGFR-1 is expressed in endothelial cells 
and pericytes, as well as monocytes / macro-
phages and osteoblasts, placental trophoblasts, 
renal mesangial cells and also in some hema-
topoietic stem cells. VEGFR-1 has been observed 
in the placenta and in uterine smooth muscle 
cells. VEGFR-1 expression is increased at the 
sites of angiogenesis. Unlike VEGFR-2 and 
VEGFR-3, hypoxia up-regulates the VEGFR-1 
gene, which is mediated by a HIF-1 –dependent 
mechanism (Gerber et al. 1997). 
5.4.2. VEGFR-2 
The second one of the three VEGF receptors, 
VEGFR-2, is structurally quite closely related to 
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VEGFR-1 (Terman et al. 1992). The mature re-
ceptor is a 230 kDa glycosylated protein (Sait et 
al. 1995, Takahashi and Shibuya. 1997), which 
has been shown to bind VEGF, VEGF-C and 
VEGF-D. Later on, the Orf-virus VEGFs, also 
called VEGF-E, have also been detected to be 
specific ligands for VEGFR-2. A growing amount 
of studies have led to the understanding that 
VEGFR-2 is actually the primary receptor medi-
ating the activating signals of VEGF on the endo-
thelium (Shibuya. 2006).  
VEGFR-2 mediates most of the endothelial 
growth and survival signals whereas based on the 
actions of VEGFR-1, as described above, it is 
commonly discussed to have a “dual role in angi-
ogenesis” (Shibuya. 2006, Zachary and Gliki. 
2001). Null-mutation of VEGFR-2 in mice results 
in embryonic death at day E8.5-E9.5 due to lack 
of development of the blood islands, embryonic 
vasculature and hematopoietic cells (Shalaby et 
al. 1995). VEGFR-2 expression is down-regulated 
in the adult vascular endothelial cells, and is 
again up-regulated in the endothelium of angio-
genic blood vessels (Partanen et al. 1999). 
Based on animal studies, also VEGFR-2 is 
highly specific to vascular endothelium through-
out the body, but besides the endothelium, 
VEGFR-2 have been localized on neuronal cells, 
osteoblasts, pancreatic duct cells, retinal pro-
genitor cells, megakaryocytes and hematopoietic 
stem cells (Ferrara. 2004). During development 
VEGFR-2 is expressed by the primitive endo-
derm, embryonic angioblasts and in the blood 
islands as well as in angiogenic vessels (Kai-
painen et al. 1993). However, it has also been 
detected in the human placenta (Dunk and Ah-
med. 2001). Unlike VEGFR-1, the expression of 
VEGFR-2 is not regulated by hypoxia (Gerber et 
al. 1997). 
5.4.3. VEGFR-3 
In humans, VEGF-C and VEGF-D also bind to 
VEGFR-3 which is an approximately 195 kDa 
protein (Tammela et al. 2005). A shorter form of 
the receptor also exists, but it is not the main one 
seen in other tissues (Eriksson and Alitalo. 1999, 
Borg et al. 1995). During embryogenesis VEGFR-
3 is expressed in both venous and lymphatic 
endothelia, but in adult humans it is restricted to 
lymphatic vessels and certain endothelial venules 
supporting the notion of a venous origin of lym-
phatic vessels (Tammela et al. 2005, Kaipainen 
et al. 1995). VEGFR-3 is also expressed in syn-
cytiotrophoblasts in the human placenta (Tam-
mela et al. 2005, Dunk and Ahmed. 2001). In 
mice, lack of VEGFR-3 causes intra-uterine death 
due to cardiovascular failure (Dumont et al. 
1998).  
5.4.4. Soluble VEGF receptors  
A soluble form of VEGFR-1 (sVEGFR-1), com-
prising only the extracellular parts of the full-
length membrane-bound receptor, has been 
found. It is expressed extremely abundantly in 
the human circulation and amniotic fluid during 
pregnancy (Kendall and Thomas. 1993, Kendall 
et al. 1996, Banks et al. 1998, Hornig et al. 
2000). A similar soluble form of VEGFR-2 
(sVEGFR-2) also exists, and it has been detected 
in vivo (Ebos et al. 2004). However, Chapters 
5.5. and 5.6. focus on the first one on them, 
sVEGFR-1. 
5.4.5. Neuropilin-1 and -2 
Neuropilin-1 (NRP-1) and neuropilin-2 (NRP-2) 
are about 120-130 kDa transmembrane glycopro-
teins, which modulate VEGF signaling, although 
the main ligands of the neuropilins have been 
found among the class 3 semaphorins. NRP-1 
serves as a receptor for some members of the 
VEGF family, namely VEGF165, VEGF-B, VEGF-E 
and PlGF -2, whereas NRP-2 mediates its actions 
targeting VEGF145, VEGF-C, VEGF-D as well as 
VEGF165 and PlGF. The neuropilins also interact 
directly with VEGFR-1 and -2, mediating their 
signal transduction (Staton et al. 2007).  
Both of the neuropilins consist of three ex-
tracellular domains (a1/a2, b1/b2, and c), a 
transmembrane region and a short cytoplasmic 
domain. They can form homodimers between 
their c-domains. Soluble neuropilins consist only 
of the a1/a2 and b1/b2 domains and compete 
with the membrane-bound forms of the recep-
tors for binding to semaphorins and VEGFs, 
thereby serving as alternative regulators of their 
availability. 
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Co-expression of NRP-1 and VEGFR-2 on endo-
thelial cells increases the binding of VEGF165 to 
VEGFR-2 about 4-fold, enhancing the VEGF165 –
mediated effects as compared to the cells ex-
pressing only VEGFR-2. Thus, NRP-1 acts as a 
co-receptor for VEGF165, not only amplifying the 
binding but also the bioactivity of VEGFR-2, 
which seems to be due to increased signaling via 
VEGFR-2. VEGF165, VEGFR-2 and NRP-1 may 
form complexes on endothelial cells potentiating 
the binding of VEGF165 to VEGFR-2. In addition, 
also NRP-2 acts as a subtype-specific receptor to 
some of the VEGFs, including VEGF165, but un-
like NRP-1, it also binds to VEGF145, VEGF-C and 
VEGF-D. Furthermore, both neuropilins bind 
PlGF-2, and NRP-1 also binds both of the VEGF-
B subtypes. PlGF-2 and VEGF-B alone do not 
bind to VEGFR-2, but they serve as ligands for 
VEGFR-1, which can complex with both of the 
neuropilins. Therefore, VEGFR-1 has been sug-
gested to take part in the neuropilin-modulated 
signaling. In addition to this, NRP-1 modulates 
angiogenesis complexing with VEGFR-1, which 
inhibits the interaction between NRP-1/VEGF165. 
The expression of NRP-1 and NRP-2 differ 
from each other in the adult vasculature: NRP-1 
is expressed mainly by arterial and NRP-2 by 
venous and lymphatic endothelium. Both neu-
ropilins are known to be over-expressed in the 
sites of physiological and pathological angio-
genesis. However, either the pathway of their 
signal transduction, gene expression or their 
definitive role in angiogenesis is not completely 
understood. 
5.5. Soluble VEGFR-1 
Soluble VEGFR-1 is a variant of the cell mem-
brane VEGFR-1 lacking its transmembrane and 
cytoplasmic domains (Kendall and Thomas. 
1993). Similarly to the membrane-bound form, it 
binds both VEGF and PlGF (Park et al. 1994, 
Kendall and Thomas. 1993). Therefore, sVEGFR-
1 acts as a natural inhibitor of VEGF and PlGF 
signaling in two different ways: First, by binding 
VEGF, the bioavailability of VEGF for VEGFR-2 
is reduced, resulting in decreased binding and 
downstream signaling through its main angio-
genic route (Kendall and Thomas. 1993). Second, 
sVEGFR-1 and VEGFR-2 are able to heterodi-
merize which causes a blockade of the signal 
transduction mediated by VEGFR-2 (Kendall et 
al. 1996). Based on this, sVEGFR-1 has been 
proposed as a “sink” for free VEGF (Hornig et al. 
2000, Vuorela et al. 2000). 
5.6. Soluble VEGFR-1 and its ligands 
during pregnancy  
In human physiology, the most remarkable 
scenes for vasculo- and angiogenesis are the 
formations of the placenta and the fetus. Both 
VEGF and sVEGFR-1 are highly expressed in the 
placenta throughout pregnancy (Vuorela et al. 
1997, Sharkey et al. 1993, Clark et al. 1996, 
Vuorela et al. 2000). Soluble VEGFR-1 is re-
leased by the early placental trophoblasts into 
maternal circulation where this can be detected 
as early as 30 days after conception (Molskness 
et al. 2004). Later on, its concentrations increase 
with advancing pregnancy (Levine et al. 2004, 
McKeeman et al. 2004, Powers et al. 2005). 
Meanwhile, also the circulating concentrations of 
total VEGF become higher (McKeeman et al. 
2004), but those of the free and biologically ac-
tive form decline already in early pregnancy 
(Levine et al. 2004, Molskness et al. 2004, 
Vuorela-Vepsalainen et al. 1999) and remain 
mainly undetectable when assessed near term 
(Levine et al. 2004, Maynard et al. 2003, Wik-
strom et al. 2007, Tsatsaris et al. 2003). Follow-
ing the first days postpartum, free VEGF can, 
again, be detected in the maternal circulation 
(Vuorela-Vepsalainen et al. 1999, Wikstrom et al. 
2007), suggesting that sVEGFR-1 disappears in 
the absence of the placenta. 
5.6.1. Expression of sVEGFR-1 and its ligands by 
the placenta  
VEGF mRNA has been found in both the endo- 
and myometrium of the non-pregnant uterus 
(Charnock-Jones et al. 1993, Harrison-Woolrych 
et al. 1995, Torry et al. 1996). The endometrial 
immunostaining for VEGF has been observed 
during the entire menstrual cycle (Li et al. 1994).  
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VEGF and sVEGFR-1 are both produced by the 
placenta. Both mRNA and protein forms of 
VEGF have been seen in the decidua (Sharkey et 
al. 1993, Ahmed et al. 1995). The first-trimester 
placental expression of sVEGFR-1 protein has 
been localized in the villous cyto- and syn-
cytiotrophoblasts and Hofbauer cells, as well as 
in decidual stromal, extravillous trophoblast, 
macrophages and glandular epithelial cells (Clark 
et al. 1996, Vuorela et al. 2000, Shiraishi et al. 
1996). Some authors have also reported immu-
nostaining for sVEGFR-1 in the stromal cells of 
the placental villi (Clark et al. 1996, Cooper et al. 
1996), although the data is contradicting (Ahmed 
et al. 1995, Shiraishi et al. 1996, Jackson et al. 
1994). Placental vascular endothelium has been 
observed to be negative for sVEGFR-1 in a num-
ber of studies (Clark et al. 1996, Vuorela et al. 
2000, Ahmed et al. 1995, Shiraishi et al. 1996, 
Cooper et al. 1996, Jackson et al. 1994).  
5.6.2. Circulating angiogenic and anti-angiogenic 
factors 
The placenta produces VEGF and sVEGFR-1 into 
the circulations of both the fetus and the mother, 
but the production is much more abundant in the 
maternal side (Brownbill et al. 2007). Starting 
from the very early pregnancy, sVEGFR-1 is se-
creted by the trophoblasts, and it can be seen in 
constantly elevating concentrations in the ma-
ternal circulation as early as the second month 
following the conception (Levine et al. 2004, 
McKeeman et al. 2004, Powers et al. 2005, 
Molskness et al. 2004). This results in a con-
comitant decline in the levels of free VEGF, al-
ready at early pregnancy. 
With advancing gestation, the levels of total 
circulating VEGF remain about 10-fold higher 
than those of its free form, which are nearly un-
detectable throughout pregnancy (Levine et al. 
2004, Molskness et al. 2004, Vuorela-Vepsäläi-
nen et al. 1999, Wikstrom et al. 2007). However, 
the circulating concentrations of the unbound 
VEGF begin to increase postpartum possibly 
because of the disappearance of its main binding 
protein in circulation, sVEGFR-1 (Vuorela-Vep-
säläinen et al. 1999, Wikstrom et al. 2007). In 
fact, sVEGFR-1 has been suggested to rapidly 
disappear from the maternal circulation after the 
delivery (Powers et al. 2005, Koga et al. 2003, 
Maynard et al. 2003, Wikstrom et al. 2007).  
The postpartum levels of sVEGFR-1 have 
been observed to be diminished when measured 
at 48 hours after delivery or to decline by 2.5% 
per hour when measured at delivery and once 
more within 48 hours (Powers et al. 2005, May-
nard et al. 2003). As the placenta is also the pri-
mary source of circulating VEGF during preg-
nancy, also the total concentrations of VEGF 
decline after delivery (Hunter et al. 2000). 
5.6.3. Soluble VEGFR-1 in association with 
maternal smoking 
Cigarette smoke, nicotine and its major metabo-
lite, cotinine, have been shown to up-regulate 
VEGF and VEGFR-1 gene expression in vitro 
(Wright et al. 2002, Conklin et al. 2002). In 
pulmonary arteries and bronchial mucosa of 
smokers the immunostaining for VEGF has been 
observed to increase (Santos et al. 2003, Calab-
rese et al. 2006). Similarly, the gene expressions 
of both VEGF and the receptor of its main sig-
naling pathway, VEGFR-2, are increased in vivo 
in the rat trachea (Wright et al. 2002). 
Smoking is associated with decreased circu-
lating concentrations of sVEGFR-1 in men and in 
non-pregnant women (Belgore et al. 2000, 
Schmidt-Lucke et al. 2005). During pregnancy, 
serum concentrations of sVEGFR-1 in the second 
and third trimesters are reduced in smokers. 
Cigarette smoke reduces the secretion of 
sVEGFR-1 under hypoxic conditions in third-
trimester placental tissue of healthy, non-
smoking women (Mehendale et al. 2007). 
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6. Soluble VEGF receptor-1 in pre-eclampsia 
During the past decade, a growing amount of 
studies have suggested that sVEGFR-1 plays an 
important role in the pathogenesis of pre-
eclampsia. In 2003, a rat model was generated to 
demonstrate that administration of sVEGFR-1 
into the circulation caused hypertension and 
proteinuria, known as hallmarks of pre-
eclampsia (Maynard et al. 2003). The excess of 
sVEGFR-1 was accompanied with a concomitant 
decrease in the concentrations of its ligands, 
VEGF and PlGF. This finding led to an assump-
tion that elevated circulating sVEGFR-1 is asso-
ciated with the development of the clinical signs 
of pre-eclampsia, soon shown in several studies. 
6.1. Placental expression of sVEGFR-
1 in pre-eclampsia 
VEGF ligands and receptors are highly expressed 
by the first trimester placenta. In immunohisto-
chemistry, the expression of VEGF, PlGF and 
VEGFR-1 protein by invasive cytotrophoblasts is 
altered in pre-eclampsia (Zhou et al. 2002). Pre-
eclampsia is associated with an up-regulation of 
sVEGFR-1 in the placental tissue (Maynard et al. 
2003, Tsatsaris et al. 2003, Ahmad and Ahmed. 
2004, Gu et al. 2008), which can be seen already 
at 11 weeks of gestation in chorionic villous biop-
sies in women with subsequent pre-eclampsia 
(Farina et al. 2008).  
It has been suggested that the increase in the 
cytotrophoblastic production of sVEGFR-1 is 
caused by hypoxia and subsequent placental 
ischemia (Nagamatsu et al. 2004). Indeed, 
sVEGFR-1 production has been noted to increase 
in models of placental hypoxia both in vitro and 
in vivo (Nevo et al. 2006). A few years ago a new 
primate model of pre-eclampsia was generated to 
demonstrate that uteroplacental ischemia results 
in pre-eclampsia –like symptoms, which was 
accompanied with a remarkable increase in cir-
culating sVEGFR-1 concentrations (Makris et al. 
2007). In addition, the amniotic fluid sVEGFR-1 
concentrations have been shown to increase in 
women with pre-eclampsia possibly reflecting 
 
 
the placental production of it (Vuorela et al. 
2000). 
The production of sVEGFR-1 by placental cy-
totrophoblasts was recently shown to comprise 
four different splice variants (named as sFlt1_v1, 
sFlt1_v2, sFlt_v3 and sFlt1_v4) of which the first 
three (sFlt1_v1-3) are up-regulated in pre-
eclampsia as compared to healthy women (Hey-
darian et al. 2009). These splice variants are 
identical in their N-termini whereas each of them 
contains a unique C-terminus. As in uncompli-
cated pregnancies, a 100 kDa variant has been 
assessed as the most abundant one in both 
plasma and culture media from placental ex-
plants of pre-eclamptic women (Rajakumar et al. 
2009). However, along with the previously 
known isoform, significantly higher amounts of a 
novel 145 kDa transcript was exhibited by 
women with pre-eclampsia. 
6.2. Circulating concentrations of 
sVEGFR-1 in pre-eclampsia 
Elevated production and release of sVEGFR-1 by 
the placenta leads to an excess of it in the mater-
nal circulation. This up-regulation of sVEGFR-1 
is associated with concomitant decrease in circu-
lating concentrations of free VEGF and PlGF 
(Maynard et al. 2003). Several studies have 
shown increased maternal circulating concentra-
tions of sVEGFR-1 in pre-eclampsia. Shortly after 
the rat model generated by Maynard et al. it was 
observed, that sVEGFR-1 concentrations are 
elevated in women with manifest symptoms al-
ready about 5 weeks before the onset of them 
(Levine et al. 2004, Chaiworapongsa et al. 2004, 
Koga et al. 2003, Maynard et al. 2003). Fur-
thermore, the amount of sVEGFR-1 correlated 
with the severity of the disease (Chaiworapongsa 
et al. 2004). Earlier studies have also measured 
circulating sVEGFR-1 concentrations postpartum 
in connection with pre-eclampsia (Levine et al. 
2004, Powers et al. 2005, Koga et al. 2003, May-
nard et al. 2003, Wikstrom et al. 2007). 
 38 
6.3. Hypothesis on the role of 
sVEGFR-1 in pre-eclampsia  
At the placental level, sVEGFR-1 has been shown 
to inhibit placental cytotrophoblast invasion and 
differentiation in primary cytotrophoblast cul-
tures (Zhou et al. 2002). Thus, it has been postu-
lated that the inhibition of VEGF blocks the en-
dothelial differentiation process of invasive cy-
totrophoblasts thereby contributing to the 
pathophysiology of pre-eclampsia. The leading 
mechanism for placental overproduction of 
sVEGFR-1 has been suggested to be hypoxia (as 
reviewed in Chapter 6.1.), although speculations 
on the role of inflammatory reasons have been 
made (Redman and Sargent. 2009).  
The excess of sVEGFR-1 in the maternal cir-
culation inhibits the actions of its ligands, VEGF 
and PlGF, leading to the general endothelial 
dysfunction seen as the classical symptoms of the 
maternal disease (hypertension, proteinuria and 
edema) (Maynard et al. 2003). The hypothesis 
has been tested in a number of settings, most 
notably, in the cell culture studies, where the 
endothelial dysfunction, induced by pre-
eclamptic sera, could be reversed by removing 
sVEGFR-1 (Ahmad and Ahmed. 2004). Symp-
toms can be triggered also by administration of 
exogenous sVEGFR-1 to pregnant mice (May-
nard et al. 2003).  
In blood samples obtained from women with 
pre-eclampsia, sVEGFR-1 concentrations seem to 
correlate with the severity of the disease (Chai-
worapongsa et al. 2004). The delivery of the 
placenta is followed by improvement of the signs 
of pre-eclampsia. Subsequently, the concentra-
tions of sVEGFR-1 decrease postpartum, al-
though sometimes in prolonged fashion in pre-
eclamptic women, at the same time as the clinical 
symptoms cease (Levine et al. 2004, Powers et al. 
2005, Koga et al. 2003, Maynard et al. 2003, 
Wikstrom et al. 2007). This supports the role of 
placental sVEGFR-1 behind the symptoms of 
pre-eclampsia. 
Soluble VEGFR-1 concentrations are also 
elevated in connection with many known risk 
factors for pre-eclampsia: they have been noted 
to be higher in nulliparous women (Wolf et al. 
2004), twin pregnancies (Maynard et al. 2008) 
and pregnancies with trisomy 13 (Bdolah et al. 
2006). 
6.4. Prediction of pre-eclampsia with 
sVEGFR-1  
Along with the accumulating data on increased 
sVEGFR-1 concentrations antedating the clinical 
signs of pre-eclampsia, several attempts to iden-
tify women in risk of the disease have been made 
based on measurements of either sVEGFR-1 
alone or in combination with other angiogenesis-
related substances, such as PlGF.  It appears to 
be proven that elevated sVEGFR-1 concentra-
tions precede the clinical symptoms by at least 5 
weeks (Levine et al. 2004), but according to 
growing amount of evidence, this time period can 
be further extended until the early second tri-
mester, especially when sVEGFR-1 is assessed in 
ratio with other angiogenesis-related substances. 
A systematic review of the literature on in-
creased sVEGFR-1 and decreased PlGF in pre-
dicting pre-eclampsia was published in 2007 by 
Widmer et al. The recommendation of the 
authors was to conduct a rigorous prospective 
trial to assess the final clinical usefulness of these 
markers for screening purposes (Widmer et al. 
2007). Interestingly, according to a review by 
Lapaire et al. in 2010, a novel automated meas-
urement system for the ratio of sVEGFR-1 and 
PlGF might soon be available in a growing num-
ber of obstetric centers providing a supplemen-
tary tool for diagnostics of pre-eclampsia 
(Lapaire et al. 2010).  However, no test has been 
proven effective in screening the risk of the dis-
ease. 
6.5. Soluble VEGF receptor-1 in 
association with IUGR 
IUGR is a common complication in especially 
early-onset pre-eclampsia, and it has long been 
recognized that pre-eclampsia and IUGR share 
many common clinical and pathologic features 
(closer described in Chapter 3.4.). Considering 
the anti-angiogenic factors, which have been 
intensively studied mostly in association with 
pre-eclampsia, there is some overlap between 
these two pregnancy complications. 
Elevated maternal circulating concentrations 
have been suggested to be associated with IUGR 
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in several studies (Chaiworapongsa et al. 2008, 
Boutsikou et al. 2006, Savvidou et al. 2006, Shi-
bata et al. 2005). Most of them, however, recog-
nize that the increase in maternal circulating 
sVEGFR-1 concentrations is smaller than in case 
of pre-eclampsia (Savvidou et al. 2006, Schlem-
bach et al. 2007). 
Umbilical and neonatal blood (assessed at 1st 
and 4th postpartial days) had increased sVEGFR-
1 concentrations as compared to appropriate for 
gestational age (AGA) full-term fetuses and neo-
nates (Boutsikou et al. 2006). In detail, elevated 
sVEGFR-1 has been proposed to be present only 
in umbilical vein and not the arteries, suggesting 
that the fetus would not contribute to the angio-
genic imbalance observed most clearly in the 
maternal circulation, where the concentrations of 
sVEGFR-1 are almost 20-fold of those in umbili-
cal arteries (Wallner et al. 2007). The presence of 
pre-eclampsia does not seem to affect the umbili-
cal venous or arterial sVEGFR-1 concentrations 
in IUGR (Schlembach et al. 2007). 
6.6. New animal models of pre-
eclampsia associated with sVEGFR-1 
6.6.1. Catechol-O-methyltransferase (COMT) and 
2-methoxyoestradiol 
Soluble VEGFR-1 has been shown to be up-
regulated in pregnant mice deficient of catechol-
O-methyltransferase (COMT) (Kanasaki et al. 
2008), which generates 2-methoxyoestradiol   
(2-ME) from hydroxyoestradiol. 2-ME is a potent 
inhibitor of angiogenesis (Fotsis et al. 1994, Mab-
jeesh et al. 2003). 2-ME inhibits the expression 
of HIF-1a resulting in subsequent down-
regulation of sVEGFR-1 production in the pla-
centa (Kanasaki et al. 2008).  
The Comt-/- mice in the study by Kanasaki et 
al. present a pre-eclampsia-like phenotype, char-
acterized as new-onset hypertension and prote-
inuria, accompanied by endothelial injury in the 
decidual arteries and renal glomeruli (Kanasaki 
et al. 2008). The symptoms of pre-eclampsia 
were reverted by 2-ME administration. The mice 
had elevated sVEGFR-1 concentrations in the 
circulation, which could also be avoided by the 
administration of 2-ME.  
In this mouse model of pre-eclampsia, it 
seems evident that the disturbance in COMT /   
2-ME –balance results in an increase in HIF-1a 
levels, followed by elevating sVEGFR-1 produc-
tion and angiogenic imbalance. This, in turn, 
leads to placental insufficiency and finally to the 
manifest symptoms of pre-eclampsia in mice. 
6.6.2. CBA/J x DBA/2 mouse model of pre-
eclampsia 
Recently, in October 2010, Ahmed and co-
workers published their finding on a novel 
mouse model of pre-eclampsia (Ahmed et al. 
2010). Complement activation, namely C5a, is a 
central event in the pathogenesis of placental and 
fetal injury in an antibody-independent mouse 
model (CBA/J x DBA/2 mice), which has previ-
ously been used as a model of recurrent miscar-
riage (Girardi et al. 2006). This complement 
activation results in dysregulation of the angio-
genic factors necessary in normal placental de-
velopment. Inhibition of this complement activa-
tion in vivo blocked the increase of sVEGFR-1 
levels, seen in the placentas of miscarried or 
IUGR pregnancies, which could even rescue the 
pregnancies. Furthermore, monocytes stimulated 
in vitro immediately released sVEGFR-1 when 
treated with products of the complement cascade 
(Girardi et al. 2006). 
The study by Giraldi et al. provided a link be-
tween complement activation and angiogenic 
imbalance, and a new insight into their role in 
the pathogenesis of pre-eclampsia. Based on 
that, Ahmed et al. postulated that DBA/J –mated 
CBA/J –female mice might also facilitate a 
mouse model of immunologically mediated pre-
eclampsia (Ahmed et al. 2010). Indeed, they saw 
that the DBA/J –mated CBA/J –female mice 
spontaneously presented multiple features of 
human pre-eclampsia (albuminuria, endothelio-
sis). These symptoms were associated with ad-
verse pregnancy outcome. Furthermore, the pre-
eclamptic features occurred only in the first 
pregnancies. 
The authors detected that the administration 
of pravastatin to these mice improves the an-
tagonistic effect of sVEGFR-1 on VEGF signaling 
and the subsequent placental and fetal injury in 
the CBA/J x DBA/2 –mice (Ahmed et al. 2010). 
It increases the release of VEGF from tro-
phoblasts ameliorating the symptoms of pre-
eclampsia: pravastatin restores the glomerular 
injury and reduces the hypersensitivity to angio-
tensin II. As a result, it preserves pregnancy. The 
authors conclude that their finding may contrib-
ute to further development of therapeutic tools in 
pre-eclampsia. 
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7. VEGF-dependent angiogenesis in human disease 
Angiogenesis is a normal process in growth, de-
velopment, the female reproductive cycle, and 
wound healing. Pathologic angiogenesis is char-
acterized as excessive, insufficient or abnormal 
neovascularization. It is a crucial event in malig-
nant, ischemic, infectious, immune and inflam-
matory disorders (Carmeliet. 2005). Angiogene-
sis is tightly regulated by the balance of a number 
of pro- and anti-angiogenic factors, such as 
VEGF and the members of VEGF family. 
7.1. Diseases associated with 
alterations in VEGF signaling 
As the VEGF family plays a central role in both 
physiologic and pathologic angiogenesis, and it 
has been considered a key factor in a number of 
processes associated with human disease. Thus, 
the blockade of this pathway is a promising 
therapeutic strategy against many of them (Car-
meliet. 2005, Hicklin and Ellis. 2005, Folkman. 
2007). In addition, some endogenous anti-
angiogenic factors, also of potential therapeutic 
use, have been identified (Folkman. 2004). 
In solid tumors, the development of a suffi-
cient vascular supply is crucial. Building of new 
vascular network is dependent on molecular 
interactions between tumor cells and their envi-
ronment (endothelial cells, macrophages, fibro-
blasts, extracellular matrix etc.), which are 
needed to influence angiogenic mechanisms by 
releasing pro-angiogenic agents. It is estimated 
that up to 60% of human cancer cells express 
VEGF. 
7.2 Therapeutic use of anti-VEGF 
agents  
7.2.1. Overview of anti-VEGF agents 
During the past decade, the growing understand-
ing of the precise mechanisms of angiogenesis 
has led to the development of new therapeutic 
substances. Blocking the signaling of VEGF has 
been shown to inhibit both physiological and 
pathological angiogenesis in a remarkable num-
ber of settings. These new biological agents influ-
ence the process of VEGF –mediated neovascu-
larization in many different ways, and the block-
ade of VEGF signaling is currently an established 
part of anti-angiogenic therapy, mostly used in 
oncology and ophthalmology (Carmeliet. 2005, 
Hicklin and Ellis. 2005, Folkman. 2007).  
Anti-angiogenic therapy can be based on tar-
geting of either the molecule or its receptors, the 
use of ribozymes to decrease receptor expression, 
or inhibitors of tyrosine kinase to block receptor 
activation (Folkman. 2007, Chu. 2009). The first 
VEGF-antagonists, brought into clinical use sev-
eral years ago, were antibodies against human 
VEGF. The very first VEGF-antagonist, bevaci-
zumab, was a chimeric murine / human antibody 
against human VEGF (Hurwitz et al. 2004). 
Bevacizumab was approved for clinical use in 
2004 and, later on, several other monoclonal 
VEGF or VEGF receptor antibodies have been 
introduced (Folkman. 2007, Chu. 2009). These 
molecules antagonize VEGF receptors or their 
respective ligands.  
Some studies have tested the blockade of 
VEGF receptors by tyrosine kinase inhibitors, 
which inhibit phosphorylation and subsequent 
signal transduction of the receptor. In addition, 
the VEGF signaling pathway has been disturbed 
by interfering intracellular VEGF mRNA, using 
ribozymes to decrease VEGF receptor expression, 
or by affecting signaling in the target cell. Also 
soluble VEGF receptor mutants or fusion-
proteins have been generated.  
7.2.2. VEGF Trap 
Soluble VEGFR-1 has been suggested to be the 
predominant regulator of the bioavailability of 
circulating VEGF. Endogenous soluble VEGFR-1 
serves as a potent inhibitor of the biological ac-
tions of VEGF (and PlGF).  Because of these 
unique binding characteristics, as compared to 
VEGF-antibodies, sVEGFR-1 has been used as a 
model to generate a VEGF ”trap” (VEGF Trap, 
 41 
Regeneron Pharmaceuticals, Inc. NY, USA), later 
named as aflibercept (or AVE0005).  
Aflibercept is a 115 kDa chimeric soluble VEGF 
receptor containing the domain 2 of VEGFR-1 
and the domain 3 of VEGFR-2 fused to an Fc 
fragment (Holash et al. 2002). The Trap mimics 
the actions of endogenous sVEGFR-1 having a 
high affinity to both VEGF-A and PlGF, and it 
can also bind VEGF-B. Its high affinity to all the 
ligands of the naturally occurring VEGFR-1 dis-
tinguishes it from the VEGF antibodies which 
bind only VEGF-A (Chu. 2009, Riely and Miller. 
2007).  
VEGF Trap has been shown to be effective in 
treating some angiogenesis-associated malignant 
tumors and ocular diseases, and many other ones 
are extensively studied in multiple ongoing clini-
cal trials analyzing its benefits (Folkman. 2007, 
Chu. 2009, Holash et al. 2002). 
7.2.3. Side effects of anti-VEGF therapy 
Hypertension is one of the most frequent side 
effects of systemic VEGF-blocking therapy. Its 
incidence and severity are dependent on the type 
of the drug, dose, and the schedule used in the 
administration of the agent (Izzedine et al. 2009, 
Gurevich and Perazella. 2009). Proteinuria is 
also a dose-related side effect occurring after 
anti-VEGF treatment and it may reflect severe 
glomerular damage (Izzedine et al. 2010). Inter-
estingly, these side effects of inhibition of VEGF 
signaling resemble the main symptoms of pre-
eclampsia; i.e. hypertension, proteinuria and 
edema (Chu. 2009, Launay-Vacher and Deray. 
2009). 
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8. Endostatin 
8.1. Structure, function and 
expression 
Endostatin was identified in 1997, when a part of 
collagen XVIII was found to represent another 
endogenous anti-angiogenic substance (O'Reilly 
et al. 1997). Two different variants of collagen 
XVIII have been identified in humans (Saarela et 
al. 1998). The short variant of collagen XVIII is a 
component of vascular and epithelial basement 
membranes whereas the long one has been 
shown to be associated with the liver.  
Endostatin is a 20 kDa product of a proteo-
lytic cleavage of collagen XVIII, thereby not sub-
ject to post-translational modifications. It is pro-
duced from the basement-membrane collagen 
XVIII. In fact, it is a fragment of the C-terminal 
region of collagen XVIII (O'Reilly et al. 1997). 
Schematic illustrations of collagen XVIII and the 
formation of endostatin are shown in Figure 4.  
Endostatin is known to suppress angiogene-
sis and branching morphogenesis in different 
settings. It inhibits vascular endothelial cell mi-
gration and proliferation in vitro (O'Reilly et al. 
1997, Ramchandran et al.  2002, Yamaguchi et 
al. 1999, Becker et al. 2005) and the function of 
endothelial cells in vivo (O'Reilly et al. 1997). 
During embryogenesis, it also regulates branch-
ing morphogenesis of epithelial cells, which has 
been studied in an ex vivo culture model of rat 
uretic bud explants (Karihaloo et al. 2001). 
Endostatin is called an “endogenous angio-
genesis inhibitor” for a good reason: based on its 
ability to block tumor growth it is one of the first 
anti-angiogenic agents proven for clinical prac-
tice in cancer therapy (Fu et al. 2009). The func-
tional receptor of endostatin on the vascular 
endothelium is α5β1 (Wickstrom et al. 2002, 
Sudhakar et al. 2003). 
Endostatin has been suggested to play a role 
in autocrine regulation of hypoxia-driven angio-
genesis (Wu et al. 2001). The same genes regu-
late endostatin and VEGF, and they are ex-
pressed in the microvascular endothelial cells 
and pericytes (Wu et al. 2001, Nomura et al. 
1995). However, opposite to VEGF, endostatin 
production has been shown to be suppressed 
under hypoxic conditions (Wu et al. 2001, No-
mura et al. 1995).  
Figure 4: 
 
A. Linear structure of the parent molecule of endostatin, collagen XVIII, which consists of an N-terminal region, a series 
of collagen-like domains, and an NC1 domain.   
 
B. Illustration of collagen XVIII carboxyl-terminus including part of the COL1 domain and the full-length NC1 domain. 
The NC1 domain, containing approximately 300 amino acid residues, consists of three functionally different subdomains: 
1. N-terminal, non-covalent trimerization domain, which is necessary for the association of trimers,  
2. Hinge region containing multiple sites, which are sensitive to different proteases, and  
3. Endostatin globular domain, covering a fragment of 20 kDa with anti-angiogenic activities.  
 
The proteolytic cleavage within the protease-sensitive hinge region of NC1 domain results in a release of fragments with 
endostatin activity. At least two steps are involved in the generation of fragments of endostatin from collagen XVIII: a 
metal-dependent early step and an elastase activity-dependent final step.  
 
C. Endostatin protein corresponds to the last 184 amino acid residues of the NC1 domain. Human endostatin protein 
monomer consists of a seven-stranded β-sheet at the center of the core structure. One side of the β-sheet is occupied by an 
α-helix (α1), while the other side is occupied by a sequence of elaborate loops, a short antiparallel β-sheet, and a second, 
shorter α-helix (α2). The protein structure also contains two disulfide bridges and a zinc-binding site located at the N-
terminus of the protein immediately adjacent to the precursor cleavage site. Interestingly, the zinc-binding site of endosta-
tin protein resembles the zinc site of matrix metalloproteinases.  
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Figure 4. Structure and generation of endostatin from collagen XVIII. 
Copyright© 2011 Hannu Koponen. All rights reserved. 
 
8.2. Endostatin in pregnancy 
During human pregnancy, both the 20 kDa and 
the 26 kDa proteolytically produced forms of 
endostatin are localized in the villous tissue in all 
stages of gestation (Pollheimer et al. 2004). It 
has been suggested, that the stromal compart-
ments of the villous placenta, as well as its vascu-
lar extracellular matrix, would represent the 
source of endostatin in regulation of angiogene-
sis during placental development. In the same 
study, endostatin was absent in all trophoblastic 
cells throughout gestation. 
 
 
 
8.3. Endostatin in association with 
pre-eclampsia and IUGR 
As previously suggested, endostatin may mod-
ulate trophoblast function (Pollheimer et al. 
2004), which is inadequate in women later de-
veloping pre-eclampsia. In manifest pre-
eclampsia, the endostatin concentrations in ma-
ternal circulation are increased (Hirtenlehner et 
al. 2003, Mahmound and Abdel-Raouf. 2006). 
However, there was no association between ma-
ternal serum endostatin and fetal IUGR. In um-
bilical and neonatal blood (the first and fourth 
postnatal days), however, endostatin con-
centrations seemed to be lower in neonates with 
IUGR as compared to those appropriate for ges-
tational age (Malamitsi-Puchner et al. 2005). In 
addition, the concentrations of endostatin in 
healthy pregnant women are similar to those of 
non-pregnant women (Mahmound and Abdel-
Raouf. 2006, Malamitsi-Puchner et al. 2005). 
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9. Angiopoietins and Tie receptors  
9.1. Introduction to Angiopoietin 
family 
The Angiopoietin family, comprising four ligands 
(Ang-1, Ang-2, Ang-3 and Ang-4) and two corre-
sponding tyrosine kinase receptors (Tie-1 and 
Tie-2) plays an important role in the develop-
ment of blood and lymphatic vasculature (re-
viewed in Thurston. 2003). They were identified 
in the middle of the 1990s and soon shown to 
play an essential role in vascular remodeling and 
maturation during angiogenesis (reviewed in 
Thomas and Augustin. 2009).  
Angiopoietins are secreted dimeric glycopro-
teins with a molecular weight of approximately 
75 kDa (Thurston. 2003). They are all either 
direct or indirect ligands for the Tie-2 receptor. 
For the Tie-1 receptor, however, no ligand has so 
far been found despite the ongoing research. 
9.1.1. Angiopoietin-1 
The first Angiopoietin to be discovered (Davis et 
al. 1996), Ang-1, has been shown to promote 
angiogenesis by recruiting periendothelial cells 
into blood vessels, thus, promoting structural 
integrity of blood vessels. Unlike VEGF, it does 
not directly induce endothelial cell proliferation 
(reviewed in Thomas and Augustin. 2009 and 
Thurston. 2003).  
Ang-1 is crucial for vascular development: 
mice lacking it die in utero due to serious vascu-
lar defects (Suri et al. 1996). Over-expression of 
Ang-1 has been studied in transgenic mice under 
the control of the keratin 14 (K14) promoter. 
These mice are viable and healthy (Suri et al. 
1998). 
Ang-1 is expressed by a variety of tissues: 
during early human development, it is expressed 
by myocardial cells, whereas later on Ang-1 can 
be found mostly in smooth muscle and other 
perivascular cells (Davis et al. 1996, Suri et al. 
1996, Maisonpierre et al. 1997, Gale et al. 2002). 
It has also been detected in association with 
some tumors and neuronal cells in the brain 
(Thomas and Augustin. 2009).  
Ang-1 binds to and activates an endothelial cell    
-specific tyrosine kinase receptor (Tie-2; Mai-
sonpierre et al. 1997). This signaling is crucial for 
postnatal hematopoiesis (Kukk et al. 1997), as 
well as in female reproduction, especially during 
the placental development (Dunk and Ahmed. 
2001). Tie-2 is further introduced in Chapter 
9.2.2. 
9.1.2. Angiopoietin-2 
Ang-2 is a competitive antagonist to Ang-1 at the 
Tie-2 receptor (Maisonpierre et al. 1997). It acts 
in an autocrine manner resulting mainly in anti-
angiogenic effects by inhibiting the Ang-1 in-
duced phosphorylation of Tie-2, which might 
cause destabilization of the vasculature. How-
ever, in non-endothelial cells Ang-2 can also act 
as an agonist to Tie-2 (Maisonpierre et al. 1997). 
During the past decade it has been established 
that Ang-2 modulates angiogenesis in a context 
and concentration dependent manner either 
acting as an agonist or an antagonist of Tie-2 
(reviewed in Thomas and Augustin. 2009 and 
Thurston. 2003).  
Mice deficient of Ang-2 survive embryogene-
sis, but they die after birth due to lymphatic de-
fects (Gale et al. 2002). However, mice overex-
pressing Ang-2 die in utero due to serious vascu-
lar defects (Sato et al. 1995). Ang-2 also plays a 
central role in lymphangiogenesis during embry-
onic development (Gale et al. 2002).  
Under physiological conditions, Ang-2 is ex-
pressed mainly by the endothelial cells at the 
sites of vascular remodeling (Maisonpierre et al. 
1997), especially in the female reproductive tract, 
as in the villous placenta (Zhang et al. 2001) and 
the ovaries (Sugino et al. 2005). It is stored in 
Weibel-Palade bodies (WPB; Fiedler et al. 2004) 
where it can be rapidly released under cytokine 
activation of the endothelium (e.g. histamine, 
thrombin). Ang-2 expression is also increased 
under pathological conditions involving blood 
vessel remodeling, especially in tumors (Thomas 
and Augustin. 2009). Opposite to Ang-1, its ex-
pression is up-regulated by hypoxia (Mandriota 
and Pepper. 1998).  
 45 
Ang-2 has been proposed to induce vascular 
sprouting and vessel destabilization in the pres-
ence of VEGF (Holash et al. 1999). At the sites of 
angiogenic sprouting, Ang-2 expression is up-
regulated along with that of VEGF, whereas their 
expression is reduced together in association 
with vascular regression. Thus, it has been pro-
posed that Ang-2 acts by interfering with Ang-1  
–induced stabilization of the vessels, which 
makes them more sensitive to other angiogenic 
cytokines, especially VEGF (Maisonpierre et al. 
1997, Stratmann et al. 1998). This theory has 
been tested in rodents using a pupillary mem-
brane as an in vivo model created for studying 
the effects of different vascular modulators (Lo-
bov et al. 2002). In this transient ocular mi-
crovessel network, Ang-2 promoted remarkable 
pro-angiogenic effects in the presence of exoge-
nous VEGF, but when the VEGF was blocked by 
its soluble receptor, sVEGFR-1, Ang-2 induced 
endothelial cell apoptosis resulting in vascular 
regression (Lobov et al. 2002). In conclusion,  
Lobov et al. suggested that VEGF can convert the 
consequence of Ang-2 stimulation from anti- to 
pro-angiogenic. 
9.1.3. Other members of angiopoietin family: 
Ang-3 and Ang-4 
Two other Angiopoietins, Ang-3 and Ang-4, have 
been identified (Valenzuela et al. 1999). They are 
actually interspecies orthologs of the same An-
giopoietin presenting an amino acid identity of 
65% and characteristic protein structures (Valen-
zuela et al. 1999). Ang-3 is present in various 
mouse tissues, and it was first thought to have 
anti-angiogenic potential acting as a context        
–dependent antagonist of Tie-2 (Valenzuela et al. 
1999).  
Ang-4 is a human counterpart of mouse Ang-
3, which has been observed to act as a relatively 
potent agonist to Tie-2 (Valenzuela et al. 1999, 
Lee et al. 2004). Ang-4 mRNA is present in high 
levels in human lungs (Valenzuela et al. 1999). A 
set of in vivo experiments on the biological ef-
fects of mouse Ang-3 and human Ang-4 revealed 
that also they can both act as agonists of Tie-2, 
but mouse Ang-3 has strong activity only on the 
endothelial cells of its own species (Lee et al. 
2004). Ang-4 induces the survival and migration 
of primary cultured human endothelial cells (Lee 
et al. 2004). 
9.2. Tie receptors 
The two endothelial cell –specific receptors of 
the Angiopoietin family, Tie-1 and Tie-2, are 
expressed by both vascular and lymphatic ves-
sels. They share identical domain structures of 
which the cytoplasmic parts are structurally quite 
close (76%) to each other, but of the extracellular 
regions, two thirds are unique (Mac Donald et al. 
2006). A schematic presentation of the mamma-
lian Angiopoietin family, including also the sol-
uble receptors (introduced above), is shown in 
Figure 5. 
9.2.1. Tie-1 receptor 
Tie-1 receptor (also called as “tie”, tyrosine kin-
ase with immunoglobulin and epidermal growth 
factor –like homology domains) is an orphan 
receptor, approximately 140 kDa of its molecular 
size (Partanen et al. 1992). It has been located in 
differentiating angioblasts and migrating endo-
thelial cells during early embryonic development 
in mice (Korhonen et al. 1994). Mice lacking Tie-
1 functions die around birth due to severe hem-
orrhages and edema, and they can be found with 
hyperactive endothelial cells suggesting that Tie-
1 has a role in regulating endothelial quiescence 
(Sato et al. 1995, Puri et al. 1995).  
Although in vivo studies point out its essen-
tial role in vascular development, no ligands have 
been found to Tie-1. It has been suggested to 
have a specific ligand-independent function in-
volving shedding of the receptor and heterodi-
meric complex formation with Tie-2, and quite 
recently, also Ang-1 and Ang-4 have been shown 
to activate Tie-1 although they do not directly 
bind to it (Saharinen et al. 2005). A soluble form 
of Tie-1 (sTie-1) has been shown to be present in 
umbilical blood and maternal serum (Vuorela et 
al. 1998). 
9.2.2. Tie-2 receptor 
Both of the Angiopoietins, Ang-1 and Ang-2 bind 
to the same site of the Tie-2 receptor, which is an 
endothelial cell -specific tyrosine kinase receptor 
also referred to as “tek” (tunica interna endothe-
lial cell kinase-2; Dumont et al. 1992, Fiedler et 
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al. 2003). Upon binding the Angiopoietins, Tie-2 
dimerizes and becomes phosphorylated in tyro-
sine residues at its C-terminal (reviewed in Tho-
mas and Augustin. 2009). 
The endothelial cell membrane-bound Tie-2 
receptor is approximately 150 kDa of its molecu-
lar size. Like Tie-1, it has an unusual N-terminal 
ligand-binding domain, a single transmembrane 
domain and an intra-cellular tyrosine kinase 
domain. This domain structure is highly con-
served among vertebrates (Lyons et al. 1998), 
which serves as important evidence for its bio-
logical importance. Indeed, disrupting the Tie-2 
function in transgenic mice models has been 
shown to result in early embryonic lethality due 
to vascular defects (Sato et al. 1995, Dumont et 
al. 1994).  
Tie-2 receptor is widely expressed by mouse 
vascular endothelial cells already during early 
embryonic development (Sato et al. 1995, Korho-
nen et al. 1994). In adults, Tie-2 is also expressed 
by vascular and lymphatic endothelial cells and 
hematopoietic cells (Thomas and Augustin. 
2009).  
The Tie-2 receptor also interplays with the 
VEGF family. First, its signaling in the endothe-
lial cells is restricted by VEGF. Second, Ang-1 
mediated Tie-2 activation inhibits VEGF induced 
signaling by its main receptor (VEGFR-2). This 
leads to stabilization of endothelial cells (Gavard 
et al. 2008). Third, Ang-2 has also been shown to 
synergize VEGF by stimulating angiogenesis, 
although in the presence of VEGF it can also act 
as an agonist of Tie-2 (Visconti et al. 2002). 
9.2.3. Soluble Tie-2 (sTie-2) 
Soluble Tie-2 (sTie-2) is present in human circu-
lation as a result of shedding of the extracellular 
region of the membrane-bound receptor. This 
shedding also reduces the amount of receptors 
available on the endothelial cell surface (Reusch 
et al. 2001). 
Soluble Tie-2, approximately 75 kDa of its 
molecular size, binds both free Ang-1 and Ang-2, 
thereby decreasing their bioavailability for the 
membrane-bound receptor (Findley et al. 2007, 
Shantha Kumara et al. 2010). Some stimuli, e.g. 
the presence of VEGF, are able to induce shed-
ding of the Tie-2 receptors leading to a decrease 
of active receptors on the cell surface (Findley et 
al. 2007). Data on the affinity of sTie-2 to its 
ligands are conflicting: one study has demon-
strated an equal sTie-2 affinity to both Ang-1 and 
Ang-2 (Maisonpierre et al. 1997), but another 
one reported a twenty-time higher affinity to 
Ang-1 than to Ang-2 (Yuan et al. 2009).  
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Figure 5. The Angiopoietin family. 
Copyright© 2011 Hannu Koponen. All rights reserved. 
Figure 5. Illustration of the mammalian Angiopoietin family including the two cell membrane Tie receptors, Tie-1 and 
Tie-2, and their four ligands: Ang-1, Ang-2, Ang-3, and Ang-4. The figure demontrates binding and subsequent conse-
quences of the Angiopoietins on Tie-2, either activating (arrows) or inhibiting it. No specific ligand is known for Tie-1, 
but it has been suggested to act in a ligand-independent manner and by complex formation with Tie-2. Ang-1 and Ang-4 
have been shown to activate Tie-1 although they do not directly bind to it. In addition to the membrane-bound Tie recep-
tors, both of them occur in soluble form (sTie-1 and sTie-2) in the human circulation. The figure also represents the 
physiological role of sTie-2 in sequestration of the Angiopoietins. In addition to Ang-1, sTie-2 can bind Ang-2, thereby 
decreasing their bioavailability for the cell surface receptor. 
 
9.3. Angiopoietins and Tie receptors 
in pregnancy 
Angiopoietin-1, Ang-2 and Tie-2, all expressed in 
the early placenta, are crucial for placental vascu-
lar development (Maisonpierre et al. 1997, Kay-
isli et al. 2006). While VEGF mediates vasculo-
genesis and has been proposed to guide fetopla-
cental vascular development, the Angiopoietins 
have been suggested to remodel the maternal 
vessels during placentation. They might also 
promote trophoblast growth and migration 
(Wulff et al. 2003). Besides the trophoblastic and 
vascular cells, the stromal macrophages have 
been shown to secrete both Ang-1 and Ang-2 
(Geva et al. 2002). 
In the placenta, Ang-1 and -2 and their 
common receptor, Tie-2, have been co-localized 
to the trophoblasts, which has been suggested to 
prove the autocrine role of the Angiopoietins in 
the placental development (Dunk et al. 2000). 
Ang-1 mRNA has been detected in the cytotro-
phoblast and syncytiotrophoblast bilayer (Geva 
et al. 2002, Dunk et al. 2000) as well as in peri-
vascular cells (Geva et al. 2002, Buhimschi et al. 
2010). Ang-2 is also secreted by smooth muscle 
and perivascular cells (Thomas and Augustin. 
2009). Its expression is decreased by hypoxia 
(Zhang et al. 2001), and it is restricted to peri-
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vascular cells of large term villi in the course of 
pregnancy (Dunk et al. 2000).  
First, Ang-2 was detected in the placenta us-
ing Northern blotting and RNA in situ hybridiza-
tion until early second trimester when it was 
located only in the syncytiotrophoblast layer of 
the chorionic villi (Goldman-Wohl et al. 2000). 
Later on, is has been shown to be expressed 
throughout gestation not only by the syn-
cytiotrophoblasts, but also the cytotrophoblasts 
and even more extensively by the perivascular 
cells (Zhang et al. 2001, Geva et al. 2002, Dunk 
et al. 2000, Buhimschi et al. 2010). Besides, Ang-
2 is also expressed by villous stromal and endo-
thelial cells (Zhang et al. 2001, Buhimschi et al. 
2010). Placental expression of Ang-2 decreases 
in the course of pregnancy (Zhang et al. 2001, 
Geva et al. 2002, Tseng et al. 2006). However, 
cultured villous explants of placentas, obtained 
from term elective Caesarean deliveries, have 
recently been shown to produce significant 
amounts of Ang-2 but not Ang-1 (Buhimschi et 
al. 2010). 
Tie-2 is expressed by angiogenic cells and cy-
totrophoblasts of the human placenta (Zhang et 
al. 2001, Kayisli et al. 2006). The Tie-2 mRNA 
expression was earlier thought to be restricted to 
the first trimester as analyzed by in situ hybridi-
zation (Zhang et al. 2001), when its mRNA has 
also been detected in the fetal and maternal 
blood vessels, and during the early second tri-
mester the Tie-2 staining was namely positive for 
endovascular trophoblasts invading the maternal 
spiral arteries (Goldman-Wohl et al. 2000). 
However, recently Tie-2 mRNA was present in 
the placenta also during the third trimester as 
analyzed by quantitative real time polymerase 
chain reaction (PCR; Buhimschi et al. 2010).  The 
expression of Tie-2 in the placenta decreases in 
the course of pregnancy (Zhang et al. 2001, Kay-
isli et al. 2006, Geva et al. 2002, Tseng et al. 
2006). Hypoxia does not affect placental Tie-2 
expression (Zhang et al. 2001). 
9.3.1. Circulating Ang-1, Ang-2 and sTie-2 
Maternal serum Ang-2 concentrations have been 
reported to be higher at 10–13 weeks (Wang et al. 
2007) and even at 32 weeks (Hirokoshi et al. 
2007) than at 38 weeks of pregnancy (Malamitsi-
Puchner et al. 2006). This indicates that their 
concentrations in the maternal circulation de-
crease with advancing pregnancy, although no 
data from longitudinal studies are available. 
Furthermore, the serum concentrations of Ang-2 
decrease rapidly after delivery (Hirokoshi et al. 
2007) indicating that the placenta is probably the 
main source of circulating Ang-2 during preg-
nancy. In amniotic fluid, Ang-1, Ang-2 and sTie-2 
are all present throughout pregnancy (Buhimschi 
et al. 2010, Pacora et al. 2009).  
9.4. Angiopoietins and Tie receptors 
in association with pre-eclampsia 
and IUGR 
In women with pre-eclampsia, alteration in the 
angiopoietin family has been detected both in the 
placental and in the systemic level: For instance, 
the placental Ang-2 expression has been shown 
to be decreased (Zhang et al. 2001), as has been 
the case also with the maternal circulating Ang-2 
levels (Hirokoshi et al. 2007, Hirokoshi et al. 
2005) when analyzed at the third trimester. In 
pre-eclamptic women, the circulating concentra-
tions of sTie-1 (Hirokoshi et al. 2005) are lower, 
whereas those of Ang-1 higher (Nadar et al. 
2005), compared to the concomitant concentra-
tions in healthy women. Besides them, the ma-
ternal sTie-2 concentrations have been assessed, 
although resulting in either lower (Gotsch et al. 
2008) or similar levels (Hirokoshi et al. 2005) as 
compared to those in pre-eclamptic women.  
Along with pre-eclampsia, pregnancy-
induced hypertension is associated with an in-
crease in circulating Ang-1, but not sTie-2, con-
centrations (Nadar et al. 2005). However, the 
circulating concentrations of Ang-2 have been 
shown to be decreased already at 10–13 weeks of 
pregnancy in women with subsequent IUGR 
(Wang et al. 2007), although the report did not 
specify whether the later IUGR was accompanied 
with pre-eclampsia or not. 
 49 
Aims of Study 
 
Pre-eclampsia is associated with alterations in 
angiogenesis-related markers in maternal circu-
lation. An excess of anti-angiogenic substances, 
especially soluble VEGF receptor-1, has been 
observed in maternal circulation after the onset 
of pre-eclampsia, probably reflecting their in-
creased placental production. Smoking reduces 
circulating concentrations of sVEGFR-1 in non-
pregnant women, and in pregnant women it 
reduces the risk of pre-eclampsia. 
  
 
 
 
 
 
 
 
 
 
The present study was designed… 
 
1. … to evaluate the potential use of ma-
ternal serum sVEGFR-1, Ang-2 and en-
dostatin in early prediction of subse-
quent pre-eclampsia (Study I, III and 
IV), 
 
2. … to evaluate whether smoking affects 
sVEGFR-1 concentrations in pregnant 
women and to study its placental secre-
tion and expression in vitro (Study II), 
and 
 
3. …to determine the biological half-life of 
endogenous sVEGFR-1 in human circu-
lation, and elucidate the concomitant 
changes in free VEGF concentrations 
(Study V). 
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Material and methods 
 
1. Subjects and specimens 
The studies were approved by the Ethical Com-
mittee of Helsinki University Central Hospital. 
All women volunteered for the study and gave 
written informed consent. Clinical data were 
retrieved by chart review of files in Helsinki Uni-
versity Central Hospital, where all women were 
treated and delivered. Gestational age was de-
termined by transvaginal ultrasound. All women 
were of Caucasian race and had singleton preg-
nancies. A summary of the blood and placental 
samples collected from the pregnant women 
(n=268) taking part in this study between the 
years 2001–2007 is given in Table 6. 
1.1. Blood samples 
1.1.1. Patient recruitment for blood sample 
collections 
For the early pregnancy blood samples, the 
women were recruited at either preoperative 
visits before induced abortion during 13–17 
weeks of gestation (V), or at routine ultrasound 
screening visits either at 12–15 weeks (I, III and 
IV) or at 19–20 weeks (II) of pregnancy. A closer 
description on the patient selections for studies I, 
III and IV is given in Chapter 1.1.2. 
The women for the late pregnancy blood 
samples were recruited at antenatal visits offered 
for counseling due to their fear of vaginal deliv-
ery (II) or during the pre-operative visits before 
elective Caesarean sections (V). 
1.1.2. Patient selection for serial blood samples in 
early pregnancy  
A total of 3 240 pregnant women in the Helsinki 
area were admitted to a blood sample collection 
during two routine ultrasound screening visits at 
13.7 ± 1 (mean ± SD) and 19.2 ± 1 weeks of gesta-
tion. The women, eventually included in the 
study, were clinically healthy, non-smoking, with 
singleton pregnancies and of Caucasian race. 
Women with any kind of underlying hypertensive 
disorder, renal disease, diabetes, or other pre-
existing disease were excluded. The samples 
collected according to the selection protocol were 
used for studies I, III and IV. 
According to the diagnostic criteria for pre-
eclampsia (given in Chapter 3.1.1.), 71 women 
(2.2%) developed pre-eclampsia, although 22 of 
them were excluded due to the reasons given 
above. Of the remaining 49 women with subse-
quent pre-eclampsia, the disease was classified 
as mild in 29 and severe in 20 patients. 
Isolated early-onset IUGR (defined in Chap-
ter 3.4.), was suspected in 73 women due to the 
findings in uterine palpation and symphysis–
fundus measurements, and the following fetal 
growth estimation by ultrasound examination at 
the outpatient clinic. Of the ones who were fur-
ther followed and closer examined at the De-
partment of Obstetrics and Gynecology, 16 
women with otherwise normal medical histories 
and uncomplicated pregnancies substantially 
delivered newborns diagnosed with IUGR. 
Fifty-nine women remaining normotensive, 
non-proteinuric and finally giving birth to neo-
nates of normal weight (± 1 SD of national aver-
age at term) were picked amongst the samples 
collected at the same gestational age. These 
women served as the control population for the 
studies.  
1.1.3. Serial sample collection after legal 
termination of pregnancy 
The legal termination of pregnancy in Study V 
was performed surgically by uterine curettage at 
15 ± 2 weeks of gestation due to trisomy 18         
(n = 2), trisomy 21 (n = 1) or socioeconomic fac-
tors (n = 2). In the sampling procedure, serial 
blood samples from each woman were taken 
before, during and following the curettage, start-
ing from an initial blood sampling 2 h before the 
administration of vaginal misoprostol. The sec-
ond sample was collected at 1 h and the third one 
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at 4 h after the start of uterine contractions. The 
fourth blood sample was taken just before the 
operation, from when on the following samples 
were collected at 5, 10, 15, 20, 30, 40, 60, 120, 
180, 360 and 720 min. Additional samples were 
drawn every 24 h for the next 6 days, and at 14 
and 21 days after the curettage. 
1.1.4. Serial sample collection after elective 
Caesarean section 
A low level Caesarean section was performed due 
to either breech presentation of the fetus, two or 
more previous Caesareans, or fear of vaginal 
delivery, for eight women participating in Study 
V. In the sampling procedure, the first one of the 
serial blood samples, taken from each participant 
in connection with her elective Caesarean sec-
tion, was drawn after placing the patient in a 
supine position. The second sample was taken 15 
minutes later, following prehydration and initia-
tion of spinal anesthesia, and the third one im-
mediately prior to the surgery. Following the 
start of the operation, blood samples were col-
lected at 15, 30, 60, 120, 180, 360, and 720 min. 
A few more samples were taken daily during the 
hospital stay (2 to 4 days).  
1.1.5. Management of blood samples 
Blood samples were collected from the antecubi-
tal vein, and if applicable, of contralateral to the 
arm used for fluid infusions (V). Plasma (II), or 
serum after and having clot at room temperature 
(I, III, IV and V), were separated by centrifuga-
tion. All samples were stored at -80°C until 
analyses.  
1.2. Placental samples 
1.2.1. Patient recruitment for placental sample 
collection 
Placental samples (II) were collected by uterine 
curettage during a legal termination of preg-
nancy performed for psychosocial reasons at the 
first trimester, 9 ± 1 weeks of gestation.  
1.2.2. Management of placental samples 
Following the curettage, the placental samples 
were immediately set in sterile phosphate buff-
ered saline (PBS) for < 2 h. The pH of the PBS 
solution was 7.4, and it was composed using the 
following substances in the given concentrations: 
0.14M NaCl, 2.7M KCl, 0.01M  Na2HPO4, and 
1.76M KH2PO4. Thus, the PBS used for the pla-
cental samples was isotonic, able to maintain the 
osmolarity of the cells. 
After a short incubation in PBS, the tissue 
samples were processed for cell culturing, dehy-
drated for paraffinization and subsequent use in 
immunohistochemical assessments, or split to 
proceed with both analyses. 
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Table 6. Summary of the blood and placental samples. 
Samples for the study were collected from 268 pregnant women between 2001–2007 
in the Department of Obstetrics and Gynecology, Helsinki University Central Hospital. 
Type 
of 
Samples 
Patient 
group 
Gestational 
age (wk) at 
sampling 
Number 
of 
women 
Samples 
per woman 
Study 
Healthy 12 – 15 51 1 I, III, IV 
non-smoking 12 – 20 28 2 I, III, IV 
women 13 – 17 5 23  V 
 16 – 20 36 1 I, III, IV 
 19 – 20 19 1 II 
 38 ±  3 22 1 II 
 39 – 41 8 12 - 14 V 
Smokers 19 – 20 20  II 
 35 ±  5 6  II 
Subsequent 12 – 15 44  I, III, IV 
pre-eclampsia 12 – 20 26 2 I, III, IV 
 16 – 20 36  I, III, IV 
Subsequent 12 – 25 11  I, III, IV 
IUGR 12 – 20 5 2 I, III, IV 
 
 
Venous blood 
 16 – 20 10  I, III, IV 
Healthy women 9 ± 1 20  II 
Placental tissue 
smokers 9 ± 1 22  II 
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2. Laboratory methods 
2.1. Detection of cytokine 
concentrations in peripheral blood  
An established assay was available for each cyto-
kine analyzed in the blood samples (I-V). Except 
for hCG (V), they were measured using a com-
mercially available enzyme-linked immunosorb-
ent assay (ELISA) purchased from R&D Systems, 
Inc. (Minneapolis, MN, USA). Serum hCG was 
assessed using a two-site immunofluorometric 
assay (Delfia®, PerkinElmer Life and Analytical 
Sciences, Inc. – Wallac Oy, Finland). 
 
Detailed information on each assay used is given 
in Table 7. 
The serum samples were diluted for Ang-1, 
Ang-2, endostatin and sTie-2 analyses (III, IV) 
according to the ratio given in Table 7. so that 
their concentrations would fall within the meas-
urable range of the assay. To reduce the impact 
of inter-assay variation, samples from both the 
patients and the controls (I, II, III, IV) or con-
secutive samples, from each woman, when appli-
cable (I, III, IV, V), were run in the same batch.  
2.2. Laboratory methods for placental 
samples 
2.2.1. Placental cell culture 
Tissue samples from the first-trimester placentas 
of smoking (n = 19) and non-smoking (n = 11) 
women (II) were washed and prepared into small 
pieces of villi (2–5 mm3), which were then incu-
bated for 24 h. The culture media (Amnio-
MAXTM-C100 Supplement; Gibco® Products, Life 
Technologies, Carlsbad, CA, USA) were then 
collected for analysis of sVEGFR-1 concentra-
tions.  
 
 
Measurements for sVEGFR-1 were performed 
using the same commercially available ELISA as 
for peripheral blood samples, described in Chap-
ter 2.1. and Table 7. Before analysis, the cell cul-
ture media were diluted 1:10 in order for them to 
fall within the measurable range of the   
sVEGFR-1 assay. The amount of sVEGFR-1 se-
creted was calculated from the measured concen-
tration and the volume of medium. The ratio of 
total sVEGFR-1 to the weight of the cultured 
tissue was calculated. 
Table 7. Description of the assays used for analyses of cytokine concentrations 
in blood samples and in placental cell culture medium. 
Protein Intra-assay 
variation (%) 
Inter-assay 
variation (%) 
Detection 
limit 
Assay Dilution 
Ang-1 > 3.3 > 6.4 63 ng/L Quantikine® ELISA 50-fold 
Ang-2 > 6.9 > 10.4 47 ng/L Quantikine® ELISA 5-fold 
hCG 3.1 3.9 2 IU/L Delfia®  
endostatin < 7.0 < 8.0 160 ng/L Quantikine® ELISA 50-fold 
sTie-2 > 5.0 > 8.3 156 ng/L Quantikine® ELISA 10-fold 
sVEGFR-1 3.2 7.7 5 ng/L Quantikine® ELISA  
VEGF 5.0 8.2 5 ng/L Quantikine® ELISA  
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2.2.2. Preparations and performance of 
immunohistochemistry 
Placental tissue samples, described above, were 
used for immunolocalization of sVEGFR-1 ex-
pression during the first trimester. The amount 
of tissue allowed the analysis in samples of 21 
smoking and 19 non-smoking women (II). Small 
pieces of placental tissues were fixed with forma-
lin, embedded with paraffin, sectioned into 5 µm 
sections on a microtome, and transferred onto 
slides for the final analyses.  
To begin the procedure, the tissue sections 
were deparaffinized with xylene and rehydrated 
in a graded series of ethanol. They were then 
immersed in citrate buffer (pH 6) to break the 
protein cross-links formed by formalin fixation, 
and heated in a microwave oven (4 x 5 min,     
550 W). The citrate solution unmasks the anti-
gens and epitopes in formalin-fixed and paraffin 
embedded tissue sections enhancing staining 
intensity of antibodies. 
The slides were cooled at room temperature 
(RT; 20 min) and washed twice in PBS (pH 7.4). 
Endogenous peroxidase activity was removed at 
RT setting the sections in hydrogen peroxide 
(H2O2, Perhydrol; Merck, Darmstadt, Germany) 
in methanol (MeOH), containing 3.2 mL of H2O2 
and 200 mL of MeOH, for 30 min. These rea-
gents were washed using PBS (2 x 5 min), after 
which the tissue sections were treated with 100 
µl of CAS-Block (Zymed® Laboratories Inc. San 
Francisco, CA, USA) at RT for 20 min. CAS-Block 
is a blocking agent which eliminates the need for 
species-specific serum blockers. 
Each section was covered with 100 µL of primary 
antibody solution against VEGFR-1 (polyclonal 
rabbit anti-VEGFR-1, 0.5 µg/mL; R&D Systems, 
Inc, Minneapolis, MN, USA) or the negative con-
trol (goat IgG, 0.5 µg/mL; DAKO, Glostrup, 
Denmark). These primary antibodies were incu-
bated at +4º C overnight, after which they were 
detected by an avidin-biotin-peroxidase –based 
method using the Vectastain ABC kit according 
to the manufacturer´s instructions (Vector Labo-
ratories, Burlingame, CA, USA). The slides were 
washed in PBS (2 x 5 min) between each step 
after applying the primary antibodies. 
The sections were first incubated for 30 min 
with 100 µL of biotinylated secondary antibody 
solution (anti-goat IgG in rabbit serum; Vector 
Laboratories) after which they were counter-
stained with hematoxylin (Mayer´s hemalum 
solution; Merck, Darmstadt, Germany) and 
mounted with Aquamount Improved mounting 
medium (BDH laboratory supplies, Poole, Eng-
land). After the actual immunohistochemistry 
and staining with hematoxylin the slides were 
washed with sterile water.  
2.2.3. Analysis of immunostaining 
Following coding and processing the placental 
samples as described above, the immunostaining 
was analyzed by two investigators, who were 
blinded to the clinical data. The intensity of im-
munoreactivity was determined semi-quantita-
tively so that positively stained cells were classi-
fied into four categories shown in Table 8. 
Table 8. Semi-quantitative classification of immunostaining of placental tissue. 
The cells, stained positively in immunohistochemistry, were classified into four categories ac-
cording to the intensity of the immunostaining. The analyses were performed by two investi-
gators, who were blinded to the clinical data associated with the samples. 
Classification category Description of immunostaining 
- no staining 
1+ weak but detectable 
2+ moderate or distinct 
3+ intense 
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3. Statistical methods 
Several statistical tests were performed in each 
study to evaluate differences in the measured 
variables, mostly concentrations of Ang-1, Ang-2, 
endostatin, sTie-2 and sVEGFR-1 (I-V). The 
analyses were mainly performed using SPSS 13.0 
for Windows® (SPSS Inc. Chicago, IL, USA).  
Besides a variety of statistical tests per-
formed on the data, a curve-fitting algorithm for 
multi-exponential decay (Microsoft Excel®;  
Microsoft Corporation, Redmond, WA, USA) was 
created for the half-life calculations (V). Details 
of the algorithm are described in Chapter 3.1. 
An effective sample size was calculated 
manually to represent a statistical power of at 
least 80% within a 2-tailed α error of 0.05. A 
two-tailed p -value < 0.05 was considered sig-
nificant. A summary of the statistical methods 
used is given in Table 9. 
3.1. Calculation of half-lives  
The half-lives for sVEGFR-1 were determined 
based on serum samples of eight healthy women 
during and after elective Caesarean sections (V). 
The calculations were performed with a curve-
fitting algorithm for multi-exponential decay 
using Microsoft Excel® (provided by Microsoft 
Office®, Microsoft Corporation). 
Soluble proteins in human compartments 
are known to represent a biphasic elimination 
pattern, probably attributable to a rapid initial 
phase caused by a clearance from the intravascu-
lar space and the following slower phase reflect-
ing its removal from the extravascular space. 
Similarly, also the sVEGFR-1 concentrations 
were postulated to consist of two exponentially 
decaying components, a rapid and a slow one, 
and a constant background, which was used as a 
basis for interpretation of the data obtained from 
the sVEGFR-1 measurements. 
 
 
 
The data were fitted to the following function: 
 
 
… where α1 and α2 denote the amplitudes of 
the decaying components, α3 the amplitude 
of the constant background and T1 and T2 
denote the corresponding half-lives.  
3.2. Analyses of distribution and 
homogeneity of variance 
The normality of distribution among continuous 
variables was analyzed either with visual obser-
vation (I, II, V) or Kolmogorov-Smirnov’s test 
(III, IV). If the distribution was skewed, a loga-
rithmic transformation corrected it in some cases 
(I, III, IV) allowing the use of a parametric test. 
After that, the homogeneity of variances in con-
centrations between the groups was analyzed 
using Levene’s test (III, IV). 
3.3. Comparisons of continuous 
variables: cytokine concentrations in 
blood and cell culture media samples 
Based on the findings concerning the distribu-
tion and the homogeneity of variances, either 
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Kruskal-Wallis analysis of variance (ANOVA; I, 
III) or Oneway ANOVA (III, IV) was performed 
to compare different cytokine concentrations 
between the study groups, and when significant, 
Student’s t –test was used for further analyses of 
differences in continuous variables, such as the 
concentrations, between the groups. Mann-
Whitney U –test was used for the comparison of 
non-parametric continuous variables (II, V).  
Differences in normally distributed and con-
tinuous variables within specific group of pa-
tients, such as concentrations in serial blood 
samples, were analyzed using paired-samples t   
–test (I, IV), whereas the changes in non-
parametric continuous variables were deter-
mined by Wilcoxon’s signed-rank test (V).  
Correlations between clinical characteristics 
and cytokine concentrations (Study IV) were 
analyzed by univariate linear regression analysis 
(IV) or Spearman rank correlation (I, III, V), the 
latter being commonly used for continuous non-
parametric variables. Parametric correlations 
were determined by Pearson’s correlation (V). 
3.4. Evaluation of risk for 
subsequent pre-eclampsia 
The χ2 test was used to determine differences in 
distributions between categorical variables. For 
example, odds ratios (OR) and 95% confidence 
intervals (95% CI) for detection of subsequent 
disease (according to an individual concentration 
above the median of a specific group of patients) 
were obtained from χ2 test (I, IV), which could 
also be utilized in calculating trends for changing 
prevalence of a disease based on cytokine con-
centrations divided into quartiles (I).  
Receiver operating characteristic (ROC) 
curve analysis was used to determine area under 
curve (AUC) for high cytokine concentrations in 
prediction of a subsequent disease (III, IV). 
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Table 9. Statistical analyses used in the study. 
 
Analysis Study 
Descriptive statistics I –V 
Logarithmic transformation I, III, IV 
Power calculations IV 
Analysis of distribution or the homogeneity of variance 
Kolmogorov-Smirnov´s test III, IV 
Visual observation I, II, V 
Levene´s test for homogeneity of variances IV 
Comparison of data within groups 
Parametric tests  
Paired-samples t –test I, IV 
Non-parametric tests  
Wilcoxon’s signed-rank test V 
Comparison of data between groups 
Parametric tests  
Student’s t –test I, II, III, IV 
One-way ANOVA* III, IV 
Non-parametric tests  
Mann-Whitney U  –test II 
Kruskal-Wallis analysis (ANOVA) III 
Correlation between different parameters 
Spearman rank correlation I, III, IV, V 
Pearson’s correlation V 
Linear regression analysis (univariate) III, IV 
Diagnostic tests 
X 2 test I, IV 
ROC curve analysis III, IV 
*Including the Post hoc –test of Bonferroni, Duncan, Dunnett, and Tukey 
ROC = Receiver operating characteristics curve 
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Results 
 
1. First and second trimester concentrations of serum 
markers in pre-eclampsia 
Soluble VEGFR-1, Ang-1, Ang-2, sTie-2 and en-
dostatin were detectable in all maternal serum 
samples analyzed in the study. At the first sampl-
ing, 13.7 ± 1 (mean ± SD) weeks of pregnancy, 
their median concentrations were statistically 
similar between the study groups. Furthermore, 
the measured concentrations were unaffected by 
subsequent IUGR diagnosis at both samplings.  
1.1. Concentrations at 2nd trimester 
(16–20 weeks of gestation) 
At 19.2 ± 1 weeks of gestation, the women with 
subsequent pre-eclampsia had higher con-
centrations of  sVEGFR-1  (p = 0.005),  Ang-2   
(p = 0.006) and endostatin (p = 0.026) than the 
women in the control group. This was also seen 
separately for sVEGFR-1 in women with later 
mild (p = 0.043) and severe (p = 0.022) pre-
eclampsia, and for endostatin concentrations 
preceding later severe pre-eclampsia (p = 0.041). 
Ang-2 concentrations correlated with sVEGFR-1 
concentrations (r = 0.306, p = 0.007). The me-
dian concentrations of the study groups, and the 
significant differences between them, at both  
12–15 and 16–20 weeks of gestation in each of 
the study groups is shown in Table 10. 
1.2. Changes in concentrations 
between serial samplings 
Samples for sVEGFR-1 and endostatin analyses 
from both sampling points were available from 
26 of 49 women with subsequent pre-eclampsia, 
5 of 16 women with subsequent IUGR, and 28 of 
59 healthy controls. Based on them, sVEGFR-1 
concentration decreased by 15% (p = 0.003) 
from the first to the second sampling in the con-
trol group. 
Serial samples for Ang-1, Ang-2 and sTie-2 
analyses were available from 23 of 49 women in 
the pre-eclampsia group, 4 of 16 women in the 
IUGR group, and 27 of 59 women healthy con-
trols. Of them, only the concentrations of sTie-2 
showed a marginal, although significant decrease 
of by 4% (p = 0.031) in the control group with 
the advancing pregnancy. Such changes between 
the samplings were not seen in women with later 
pre-eclampsia or IUGR. 
1.3. Prediction of pre-eclampsia 
1.3.1. Odds ratios for sVEGFR-1 and Ang-2 
concentrations 
Women with sVEGFR-1 and/or Ang-2 concentra-
tions above the median of the groups had an 
elevated risk of pre-eclampsia, as the odds ratio 
(OR) for sVEGFR-1 was 2.1 (0.8–5.6 = 95% con-
fidence interval, CI) and that for Ang-2 was 2.9 
(1.6–7.3). Severe pre-eclampsia was character-
ized with even higher ORs being 4.1 (1.1–15.6) for 
sVEGFR-1 and 4.3 (1.1–16.3) for Ang-2. 
Combining the two proteins, sVEGFR-1 and 
Ang-2, the ORs were improved to 4.7 (1.5–14.4;  
p = 0.007) in later pre-eclampsia and to 7.5  
(1.9–29.1; p = 0.004) for subsequent severe pre-
eclampsia. 
The quartile analysis also confirmed the 
value of sVEGFR-1 in identifying women at risk 
of pre-eclampsia (p = 0.033) and severe pre-ec-
lampsia (p = 0.018). However, the ratios of Ang-1 
to Tie-2, Ang-2 to Tie-2 or Ang-1 to Ang-2 con-
centrations did not increase the predictive value 
of the individual markers. 
1.3.2. ROC analysis of Ang-2 and endostatin at 
2nd trimester 
For further validity of elevated Ang-2 and en-
dostatin concentrations in screening of pre-
eclampsia, a receiver operating characteristics 
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(ROC) curve was applied to the data received 
from the women in the control and pre-
eclampsia groups. It was further used to calculate 
the area under the curve (AUC) for Ang-2 and 
endostatin for diagnosis of pre-eclampsia. The 
ROC curve was also used to determine the opti-
mal cut-off value, giving the best combina-tion of 
sensitivity and specificity, of maternal serum 
endostatin concentrations in the prediction of 
subsequent disorder. 
In the ROC analysis, the AUC for Ang-2 was 0.69 
(95% CI = 0.57–0.82; p = 0.007) whereas that 
for endostatin was 0.64 (0.50–0.81) to identify 
subsequent pre-eclampsia.  
The optimal cut-off values were determined 
and used for calculations of sensitivity and speci-
ficity of endostatin concentrations, which were 
80% and 52% (cut-off value = 58.0 ng/L) in pre-
eclampsia, and 8% and 65% (cut-off value =   
65.5 ng/L) in the severe form of the disease. 
 
2. Effects of smoking on sVEGFR-1 during pregnancy 
 
2.1. Effects of maternal smoking on 
circulating sVEGFR-1 concentrations 
in pregnant women 
Maternal plasma sVEGFR-1 concentrations in-
creased from the second to the third trimester in 
both smoking (p < 0.05) and non-smoking         
(p < 0.001) women. However, the median con-
centration of sVEGFR-1 was independent on 
maternal smoking at both the second and the 
third trimester. 
2.2. Effects of maternal smoking on 
placental sVEGFR-1 secretion 
All placental tissue samples secreted sVEGFR-1 
in measurable concentrations. The ratio of total 
sVEGFR-1 (ng) per tissue weight (as described in 
Methods, Chapter 2.2.1.) did not alter between 
the smokers and non-smoking women. Although 
the amount of sVEGFR-1 was higher in smokers, 
this difference was not statistically significant. 
2.3. Effects of maternal smoking on 
placental sVEGFR-1 expression in 
vitro 
In immunohistochemistry, we found sVEGFR-1 
expression mainly in the villous cytotro-
phoblasts. The staining located in the cytotro-
phoblasts was negative in one of the samples in 
each group. Otherwise the intensity of immu-
nostaining varied between 1+ (weak but detect-
able) and 3+ (intense) the pattern of which was 
independent on maternal smoking before the 
termination of pregnancy. The vascular endothe-
lium and the stroma of the placental villi were 
negative for sVEGFR-1 staining whereas a few 
samples in both groups presented weak im-
munoreactivity in the villous syncytiotro-
phoblasts layer. 
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Table 10. Maternal serum concentrations of Ang-1, Ang-2, endostatin, sTie-2, and sVEGFR-1 
at 12–15 (“first sampling”, range) and 16–20 weeks of gestation (“second sampling”) in women 
with subsequent pre-eclampsia (mild or severe) or IUGR compared to normotensive women. 
Controls Pre-eclampsia IUGR 
 
 All Mild Severe 
concomitant 
IUGR 
 
First sampling at 12–15 weeks of gestation 
Number of 
samples 
50 41 27 14 10 11 
Median 27.8 35.0 26.7 35.8 36.5 23.9 
Ang-1 
(µg/L) 
IQR 18.3 – 34.9 22.0 – 42.2 17.1 – 42.4 26.2 – 43.4 26.4 – 50.8 22.0 – 35.2 
Number of 
samples 
50 41 27 14 10 11 
Median 33.2 38.8 38.8 38.8 31.5 30.0 
Ang-2 
(ng/mL) 
IQR 24.7 – 43.1 26.0 – 48.9 26.0 – 55.9 25.8 – 43.7 24.8 – 41.8 20.8 – 48.5 
Number of 
samples 
51 44 28 16 10 11 
Median 59 66 69 58 ND 68 
Endostatin 
(µg/L) 
IQR 53-69 56-74 62-76 53-63 ND 44-78 
Number of 
samples 
50 41 27 14 10 11 
Median 18.2 17.8 17.5 18.6 18.5 19.3 
sTie-2 
(ng/mL) 
IQR 16.6 – 20.8 15.9 – 20.3 16.2 – 20.5 15.5 – 20.4 15.6 – 22.0 16.5 – 21.5 
Number of 
samples 
51 44 28 16 10 11 
Median 432 481 463 489 491 486 
sVEGFR-1 
(ng/L) 
IQR 236 – 575 384 – 628 364 – 662 411 – 591 381 – 578 293 – 582 
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Second sampling at 16–20 weeks of gestation 
Number of 
samples 
36 31 16 15 8 9 
Median 26.0 31.4 33.7 30.6 31.7 32.3 
Ang-1 
(µg/L) 
IQR 16.6 – 34.6 23.9 – 35.0 23.7 – 35.6 23.9 – 32.9 25.3 – 51.9 23.7 – 38.3 
Number of 
samples 
36 31 16 15 8 9 
Median 17.7  25.0 a 23.5 29.0 b 26.6 31.0 c 
Ang-2 
(ng/mL) 
IQR 10.8 – 27.4 19.3 – 39.5 18.9 – 42.7 20.2 – 36.6 14.6 – 35.1 19.3 – 36.5 
Number of 
samples 
36 31 16 15 8 10 
Median  58 68 d 65 69 e ND 56 
Endostatin 
(µg/L) 
IQR 45 – 70 62 – 72 62 – 69 67 – 73 ND 45 – 71 
Number of 
samples 
36 31 16 15 8 9 
Median 18.1 17.1 17.4 17.1 15.8 18.2 
sTie-2 
(ng/mL) 
IQR 16.2 – 19.9 16.2 – 19.9 16.4 – 19.9 15.7 – 21.3 13.6 – 20.4 14.7 – 19.9 
Number of 
samples 
36 31 16 15 8 10 
Median  296 436 f 340 g 497 h 532 349 
sVEGFR-1 
(ng/L) 
IQR 184 – 508 282 – 699 285 – 750 235 – 699 235 – 988 261 – 487 
 
p –values compared to controls: 
a p = 0.006  b p = 0.016 
c p = 0.038  d p = 0.026 
e p = 0.041  f  p = 0.005 
g p = 0.043  h p = 0.022 
 All Mild Severe 
concomitant 
IUGR 
 
IQR = interquartile range Controls Pre-eclampsia IUGR 
p –values in comparison to controls are based on Student’s t –test, and after logarithmic transformation if tested with 
skewed distribution.  
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3. Sequential changes in sVEGFR-1 concentrations after 
pregnancy 
3.1. Disappearance of sVEGFR-1 
from maternal circulation after 
elective Caesarean section 
The baseline serum sVEGFR-1 concentration at 
term was 11 180 ng/L (6 380–17 480 ng/L; me-
dian, range) from where it declined slightly due 
to the fluid infusions. However, at 30 min (18–72 
min) after the beginning of the operation it had 
increased by 20% (8–47%, p = 0.028) in six of 
the patients. At its highest, the median   
sVEGFR-1 concentration in maternal serum was 
15 390 ng/L (6 910–17 680 ng/L) and a similar 
elevation in its levels was later seen also in the 
two other patients.  
As there was no simultaneous increase in se-
rum hCG, the half-lives of sVEGFR-1 were de-
termined based on the measurements after this 
initial increase. The elimination of sVEGFR-1 
was biphasic, comprising two exponentially de-
caying components that represent its biological 
half-lives, a rapid and a slow one (described in 
more detail in Figures 6 and 7). Furthermore, the 
calculated half-lives were similar to those of hCG 
observed in both the present and a previous 
study (Korhonen et al. 1997). 
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Figure 6. The two components (rapid and slow) of the biphasic half-life of circulating 
sVEGFR-1 and hCG after term pregnancy in eight healthy women. 
Figure 6. Individual half-lives of maternal serum sVEGFR-1 and hCG were calculated in the serum samples of eight 
healthy Finnish women undergoing elective Caesarean sections at 40 ± 0.4 (mean ± SD) weeks of pregnancy using a 
curve-fitting algorithm. The biphasic half-lives had two exponentially decaying components, the rapid and the slow one, 
here expressed in minutes, for both sVEGFR-1 and hCG. Their half-lives were quite similar to each other, but this notion 
was not statistically significant. However, a positive correlation was observed between the two half-life components of 
hCG (r = 0.76, p = 0.028; Spearman’s rank correlation). 
 
3.2. Sequential changes in sVEGFR-1 
and concurrent VEGF levels after 
induced abortion 
In the five pregnant women undergoing legal 
termination of pregnancy at 15 ± 2 (mean ± SD) 
weeks of gestation, the baseline concentrations of 
serum sVEGFR-1 and VEGF were 1 000 ng/L 
(200–1 430 ng/L; median, range) and 21 ng/L 
(14–28 ng/L), respectively. However, following 
the beginning of the contractions there was a 
25% (12–29%, p = 0.043) increase in sVEGFR-1 
concentration at 1 h, whereas no change in the 
amount of VEGF was seen. Such an elevation in 
the sVEGFR-1 levels was previously observed 
after the beginning of the Caesarean section, as 
described in Chapter 3.1., although the baseline 
of the 3rd –trimester sVEGFR-1 levels appeared 
about 10-fold higher compared to those during 
the later first trimester. 
After this initial rise in serum sVEGFR-1 
concentrations, the levels decreased simulta-
nously with an increase in free VEGF concentra-
tions, with a highly significant negative correla-
tion to each other (r = -0.90, p < 0.0001). A con-
stant level for VEGF seemed to be reached be-
tween the 3rd and 6th day and that of sVEGFR-1 
in 6 days after the operation as analyzed graphi-
cally from the curve drawn on the basis of the 
data. 
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Figure 7. Biphasic elimination of endogenous sVEGFR-1  
from maternal circulation after term pregnancy. 
 
 
Figure 7. The elimination of endogenous sVEGFR-1 from maternal circulation during and after Caesarean 
delivery was composed of a rapid half-life of 3.4 h (2.2 – 7.5 h; median, range) and a slow one of 29 h      
(17–94 h). The figure represents these two exponential curves (using a logarithmic scale) of the biphasic 
disappearance of sVEGFR-1 in one of the patients (Patient 5). Her individual rapid half-life was 7.2 h     
(430 min) and the slow one 34 h (2 050 min). After an initial increase in sVEGFR-1 concentrations during 
the operation, her sVEGFR-1 concentration was 15 880 ng/L from where on the half-lives were calculated. 
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Discussion 
 
1. Serum markers of pre-eclampsia in early pregnancy 
 
On the basis of the different pathophysiological 
phenomena associated with pre-eclampsia, sev-
eral circulating biochemical markers, exhibiting 
placental and endothelial dysfunction, activation 
of coagulation, or inflammation, have been 
tested for their ability to predict the disease. 
Among many others, such markers include fi-
bronectin, fetal DNA, hemoglobin or hematocrit, 
hCG, estriol, leptin, plasminogen activator, PlGF, 
and uric acid (Meads et al. 2008, Chappell et al. 
2002). Circulating concentrations of these bio-
markers have been noted either to increase or 
decrease several weeks before the clinical mani-
festation of pre-eclampsia. However, in system-
atic reviews the evidence has been too week to 
make recommendations on their clinical use in 
screening (Meads et al. 2008, Conde-Agudelo et 
al. 2004). In addition, numerous clinical and 
biophysical tests have been introduced as prom-
ising candidates for risk assessments of pre-
eclampsia. Nevertheless, neither the biochemical 
nor the other markers have been specific or pre-
dictive enough, and so far, no single test has 
reached the clinical standards of a screening test 
for pre-eclampsia (Meads et al. 2008, Conde-
Agudelo et al. 2004).  
Pre-eclampsia is associated with an angio-
genic imbalance and alterations in related bio-
markers in the maternal circulation. In this 
study, we found that the maternal serum concen-
trations of Ang-2, endostatin and sVEGFR-1, 
three central anti-angiogenic factors, were in-
creased already at 16 – 20 weeks of pregnancy, 
preceding the onset of pre-eclampsia. Further-
more, they could be used to identify women at 
risk of the disorder with a moderate precision. 
1.1. Concentrations of maternal 
serum sVEGFR-1, Ang-2 and 
endostatin at 1st and 2nd trimesters 
The first one of the angiogenic-related markers 
chosen for this study was sVEGFR-1 which had 
become known as an inhibitor of the actions of 
VEGF and PlGF in a rat model and the accompa-
nying experiments by Maynard et al. in 2003 
(Maynard et al. 2003). The researchers had 
shown that administration of sVEGFR-1 into the 
circulation of pregnant rats caused the classic 
signs of pre-eclampsia: hypertension and prote-
inuria (Maynard et al. 2003). Similarly, sVEGFR-
1 concentrations had been shown to be elevated 
in women with manifest symptoms and already 
about 5 weeks before the onset of them (Levine et 
al. 2004, Chaiworapongsa et al. 2004, Koga et al. 
2003, Maynard et al. 2003). Furthermore, the 
amount of sVEGFR-1 correlated with the severity 
of the disease (Chaiworapongsa et al. 2004).  
As assumed by the previous data, sVEGFR-1 
seemed likely to reflect the placental events asso-
ciated with pre-eclampsia. Thus, we hypothe-
sized that similar excess might be present in the 
systemic level long before the development of the 
clinical syndrome. Indeed, based on our meas-
urements, women with subsequent pre-
eclampsia had higher serum sVEGFR-1 concen-
trations at 16–20 weeks of gestation (p = 0.005) 
than the group of healthy controls, which could 
also be seen in the subgroup analysis of women 
with mild (p = 0.043) or severe (p = 0.022) pre-
eclampsia.  
Similarly, we found that also Ang-2, an anti-
angiogenic growth factor, is increased in mater-
nal circulation at the early second trimester,    
16–20 weeks of gestation, preceding the onset of 
pre-eclampsia (p = 0.006). The finding was con-
troversial to the earlier data as placental Ang-2 
expression and maternal circulating Ang-2 levels 
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have been shown to be decreased at the third 
trimester in connection to pre-eclampsia (Zhang 
et al. 2001, Hirokoshi et al. 2007, Hirokoshi et al. 
2005). However, our results might reflect the 
overall elegant angiogenic balance at this specific 
stage of pregnancy differing from that of the 
third trimester, presented in the referred studies. 
It is also worth noting that in uncomplicated 
pregnancy, maternal serum Ang-2 concentra-
tions seem to decrease with advancing pregnancy 
(Wang et al. 2007, Hirokoshi et al. 2007, Ma-
lamitsi-Puchner et al. 2006).  
Besides sVEGFR-1 and Ang-2, we observed 
that circulating maternal endostatin concentra-
tions were elevated at this point of early second 
trimester in association with subsequent pre-
eclampsia (p = 0.026), and especially its severe 
form (p = 0.041). Our results are in line with the 
earlier data according to which circulating en-
dostatin is increased in women with manifest 
pre-eclampsia (Hirtenlehner et al. 2003). In 
accordance with this previous study concerning 
the third trimester, we did not find any associa-
tion between maternal serum endostatin and 
subsequent IUGR. 
The studied anti-angiogenic markers have 
been suggested to be produced by the placenta. 
Therefore, we measured their serum concentra-
tions around 14 weeks of gestation, when early 
placentation has taken place and steroid produc-
tion has shifted from corpus luteum to the pla-
centa, knowing that it has been suggested that 
some placental defect associated with pre-
eclampsia might operate already at this point of 
pregnancy. We performed the second sampling 
at 19 gestational weeks, when pre-eclampsia 
should be evident on the placental level. None of 
the biomarkers were elevated preceding pre-
eclampsia around 14 weeks of pregnancy, but 
about 5 weeks later, at the second sampling 
around 19 weeks of pregnancy, the subsequent 
syndrome had become evident in the systemic 
level. Thus, the placental events associated with 
the development of pre-eclampsia could be 
measured about 13 weeks before its clinical on-
set. This result is consistent with the assump-
tions that an excess of anti-angiogenic factors 
contribute to the etiology of pre-eclampsia. 
1.2. Potential serum markers in 
prediction of subsequent pre-
eclampsia 
Besides the increased concentrations of the stud-
ied anti-angiogenic factors prior to the manifes-
tation of clinical pre-eclampsia, we showed that 
their elevated concentrations at 16 - 20 weeks of 
pregnancy were associated with an increased risk 
of this disorder. Based on odds ratios, an ele-
vated sVEGFR-1 concentration was assessed to 
hold an increased risk of pre-eclampsia. The 
same was observed also for Ang-2. In the ROC 
analysis, Ang-2 was also somewhat predictive of 
later pre-eclampsia. Using the optimal cut-off 
values determined from the curve drawn for 
endostatin, its sensitivity and specificity were 
80% and 52%, and identifying the women pre-
senting the severe form of the disease alone only 
slightly improved the specificity (80% and 65%, 
respectively). Thus, the predictive value of these 
individual markers can be pronounced as mod-
erate at the best. All in all, studies based on 
larger population are needed to determine 
whether these markers could be used in clinical 
practice for the prediction of pre-eclampsia. 
Interestingly, we noticed that combining the 
two biomarkers, sVEGFR-1 and Ang-2, some-
what improved the accuracy of these markers 
compared to using one of them alone. Similar 
findings have been reported on the ratio of 
sVEGFR-1 to PlGF in several studies (De Vivo et 
al. 2008, Moore Simas et al. 2007, Levine et al. 
2006). As it has been shown that a blockade of 
both VEGF and PlGF is required to produce pre-
eclampsia –like symptoms in pregnant rats, it is 
likely that namely the blockade of PlGF signaling 
plays an important role in the pathogenesis of 
sVEGFR-1 –mediated endothelial dysfunction 
(Maynard et al. 2003).  
Soluble VEGFR-1 has been thought to play a 
key role in the pathogenesis of pre-eclampsia 
(Maynard et al. 2005). Upon the publication 
process of our results on sVEGFR-1 (Study I), a 
growing number of papers were published sup-
porting our results. However, by 2007 there were 
only 10 of 184 studies, including ours, with 
sVEGFR-1 levels measured retrospectively at 
different gestational ages comparing the results 
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between the women with subsequent pre-
eclampsia to the ones with uneventful pregnan-
cies (reviewed by Widmer et al. 2007). This sys-
tematic review of the literature on increased 
sVEGFR-1 and decreased PlGF concentrations in 
predicting pre-eclampsia concludes that a pro-
spective trial is still needed to evaluate the clini-
cal usefulness of them in screening purposes 
(Widmer et al. 2007).  
Lately, measurements of sVEGFR-1 and 
PlGF with novel commercial assays have been 
proposed as new promising tools in early screen-
ing of pre-eclampsia (Schiettecatte et al. 2010, 
Sunderji et al. 2010) and such an automated 
measurement systems are currently being inves-
tigated for clinical use (Lapaire et al. 2010). 
However, their predictive value may still fall 
under that acquired for proper diagnostic tests. 
As pre-eclampsia has been suggested to be a 
multifactorial disease, perhaps the best predic-
tive tool could be created by combining a number 
of markers, including those of the activated co-
agulation or inflammation, with the ones reflect-
ing the angiogenic imbalance. Importantly, as-
sessing specifically the women already at risk of 
pre-eclampsia might bring new insight into the 
use of such combinations. 
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2. Effects of smoking on sVEGFR-1 during pregnancy 
Cigarette smoking has been observed to decrease 
circulating sVEGFR-1 concentrations in men and 
in non-pregnant women (Belgore et al. 2000, 
Schmidt-Lucke et al. 2005). In addition, cigarette 
smoke, nicotine and its major metabolite, co-
tinine, have been shown to up-regulate VEGF 
and VEGFR-1 gene expression in vitro (Wright et 
al. 2002, Conklin et al. 2002). However, cigarette 
smoking during pregnancy reduces the risk of 
pre-eclampsia (Conde-Agudelo and Belizan. 
2000). As smoking affects the expression of 
sVEGFR-1, which is increased in pre-eclampsia, 
we studied whether it affects circulating 
sVEGFR-1 concentrations in pregnant women. 
We then further evaluated whether the placental 
expression or secretion of sVEGFR-1 are also 
altered in connection to smoking. 
Based on our results, maternal smoking did 
not statistically affect the plasma concentrations 
of sVEGFR-1. This finding is contrary to an 
earlier study reporting lower sVEGFR-1 concen-
trations in serum of smokers during the mid- and 
third trimesters (Powers et al. 2005), possibly 
reflecting different smoking habits between these 
populations or the small number of smokers in 
our study. However, there was a tendency to-
wards decreased sVEGFR-1 concentration among 
smokers in the third trimester, but the small 
sample size (n = 6) might make the statistical 
significance impossible to detect. Interestingly, 
smoking was recently associated with alterations 
in the concentrations of pro-angiogenic factors 
during early pregnancy, but no obvious associa-
tion with subsequent pre-eclampsia was ob-
served (Jeyabalan et al. 2008). Our data also 
indicates that the protective effect of smoking 
against pre-eclampsia may be mediated by fac-
tors other than sVEGFR-1, but we cannot exclude 
its role in the disease process due to our indirect 
study setting. 
Placental tissue has been observed to secrete 
sVEGFR-1 (Vuorela-Vepsalainen et al. 1999, 
Mehendale et al. 2007, Gu et al. 2008). In our 
study, the first-trimester placental sVEGFR-1 
secretion in tissue samples collected from smok-
ing women tended to be higher than in those of 
non-smoking women. However, this difference 
was not statistically significant. Nicotine and its 
stable metabolite cotinine, have toxic effects on 
the placenta (Zdravkovic et al. 2005) and mater-
nal smoking affects placental development im-
pairing the function of cytotrophoblasts (Jauni-
aux and Burton. 2007, Zdravkovic et al. 2005). 
Cigarette smoke also reduces the secretion of 
sVEGFR-1 under hypoxic conditions in third-
trimester placental tissue of non-smoking 
women (Mehendale et al. 2007).  Based on our 
results, we cannot exclude the effect of smoking 
on placental production of sVEGFR-1. 
In our study, we detected sVEGFR-1 expres-
sion in first-trimester placental tissue mostly in 
the cytotrophoblast layer. In a minority of sam-
ples immunostaining was also seen in the syn-
cytiotrophoblast layer and decidua. However, the 
pattern or the intensity of immunostaining were 
not observed to be altered in connection to ma-
ternal smoking, and the staining pattern was 
quite similar to that previously described by us 
and some other authors (Clark et al. 1996, 
Vuorela et al. 2000, Cooper et al. 1996). Further 
direct studies on samples from both smoking and 
non-smoking women with pre-eclampsia would 
give a closer view to the potential protective role 
of sVEGFR-1 in the placental level. 
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3. Biological half-life of endogenous sVEGFR-1 in human 
circulation and potential implications on anti-angiogenic 
therapy 
3.1. Biphasic elimination of 
endogenous sVEGFR-1 from 
circulation 
Circulating concentrations of sVEGFR-1 have 
been assessed postpartum in connection with 
pre-eclampsia, when its third-trimester levels are 
much higher compared to healthy women at the 
same gestational age (Levine et al. 2004, Powers 
et al. 2005, Koga et al. 2003, Maynard et al. 
2003, Wikstrom et al. 2007). As the maternal 
sVEGFR-1 concentrations decrease rapidly 
within a week after delivery, also following un-
complicated pregnancies, this excess of circulat-
ing sVEGFR-1 is likely to be of placental origin 
(Powers et al. 2005, Koga et al. 2003, Maynard et 
al. 2003, Wikstrom et al. 2007). In fact, 
sVEGFR-1 was seen to decline within 48 h after 
delivery (Maynard et al. 2003), and it was re-
duced by 2.5% per hour according to two meas-
urements at the time of delivery and after 48 h 
(Powers et al. 2005). However, a precise half-life 
for endogenous sVEGFR-1 was not determined in 
these studies. 
Caesarean section provides a unique setting 
for analyzing the disappearance of endogenous 
sVEGFR-1 as the circulating concentrations of 
this pregnancy-associated protein are in this case 
markedly higher compared to those of non-
pregnant stage. Furthermore, in this setting, the 
main source of sVEGFR-1, the placenta, is 
rapidly removed during the operation. Based our 
results, the disappearance of sVEGFR-1 is bipha-
sic, representing two exponentially decaying 
components for the half-lives, a rapid half-life of 
3.4 h and a slow one of 29 h.  
In our setting, the fluid infusion preceding 
the Caesarean section was followed by a minor 
decrease in sVEGFR-1 concentrations. Addition-
ally, a transient increase in the circulating 
sVEGFR-1 levels was seen right after the begin-
ning of the operation, similar to the one seen in 
connection with the beginning of contractions 
during the induced abortion. This phenomenon 
might be due to the manipulation of the placenta, 
which contains sVEGFR-1 in huge amounts. In-
terestingly, there was no such rise in serum hCG 
levels, which were measured as a reference. In 
fact, the obtained half-lives of sVEGFR-1 resem-
bled the ones of hCG in our study as well as in a 
previous study (Korhonen et al. 1997). Further-
more, we speculated that if there was a suffi-
ciently long delay before the fitting procedure 
this transient increase would be attenuated and it 
would not affect the proper evaluation of the 
half-lives.  
The half-lives of sVEGFR-1 were calculated 
after the initial increase in its concentrations. 
The disappearance of sVEGFR-1 was found 
biphasic, which is usual for proteins in human 
circulation. This has been suggested to reflect a 
rapid initial phase of elimination caused by the 
clearance of the protein from the intravascular 
space and a slower phase associated with the 
removal of it from the extravascular space. The 
route of elimination for sVEGFR-1 has not been 
determined, although according to its size, which 
is 110 kDa (Kendall and Thomas. 1993), it is too 
big to cross the glomerular barrier and enter the 
urine. Thus, it is probably mostly eliminated 
either by the liver and/or the reticuloendothelial 
system. 
3.2. Sequential changes in sVEGFR-1 
and VEGF after induced abortion 
During pregnancy, the concentrations of free 
VEGF fall already at the beginning and remain 
low until term (Levine et al. 2004, Molskness et 
al. 2004, Vuorela-Vepsäläinen et al. 1999), prob-
ably as a result of binding to a naturally occuring 
antagonist, sVEGFR-1. This notion was further 
supported by our study indicating that the serum 
concentrations of sVEGFR-1 and free VEGF after 
legal termination of pregnancy present a highly 
negative correlation to each other. The circulat-
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ing concentrations of free VEGF rise to its non-
pregnant level postpartum possibly resulting 
from the disappearance of its binding protein, 
sVEGFR-1 (Vuorela-Vepsäläinen et al. 1999, 
Wikstrom et al. 2007). Our study provides con-
firming evidence that there is an excess of 
sVEGFR-1 during pregnancy, but shortly follow-
ing the delivery free VEGF dominates in the ma-
ternal circulation. However, it is worth noting 
that although sVEGFR-1 has been proposed as 
the predominant regulator of the bioavailability 
of circulating VEGF, other soluble receptors in 
the VEGF family, sVEGFR-2 and soluble neuro-
pilin-1 (sNRP-1), may also contribute to this re-
gulation (Ebos et al. 2004, Gagnon et al. 2000). 
Furthermore, sVEGFR-1 itself has additional 
ligands as it also binds VEGF-B and PlGF. 
3.3. Anti-angiogenic therapy and 
sVEGFR-1 
There is an elegant balance between pro- and 
anti-angiogenic factors regulating a number of 
biological processes. For example, angiogenesis 
and the VEGF family play an essential role in 
tumor growth and metastasis. Therefore, the 
blockade of this pathway is a promising thera-
peutic strategy for inhibition of tumor growth 
(Carmeliet. 2005, Hicklin and Ellis. 2005, Folk-
man. 2007). Anti-VEGF therapy can target either 
the molecule or its receptors, decrease receptor 
expression or block the activation of the receptor 
(Folkman. 2007, Chu. 2009). Interestingly, 
VEGF-blocking therapy has side effects resem-
bling the symptoms of pre-eclampsia (hyperten-
sion, proteinuria and edema). This phenomenon 
probably reflects similar mechanisms of the 
endothelial dysfunction in case of pre-eclampsia 
and the adverse effects of anti-angiogenic 
therapy (Chu. 2009, Launay-Vacher and Deray. 
2009). Thus, data on the kinetics of endogenous 
sVEGFR-1 might also be valuable in further stud-
ies on pregnancy complications. 
In fact, sVEGFR-1 has already been used as a 
model to generate a VEGF ”trap”, later named as 
aflibercept (or AVE0005). It is a 115 kDa chi-
meric receptor, which contains the domain 2 of 
VEGFR-1 and the domain 3 of VEGFR-2 fused to 
an Fc fragment (Holash et al. 2002). VEGF Trap 
mimics the action of endogenous sVEGFR-1 as it 
has a high affinity to both VEGF and PlGF. This 
substance has been shown to be effective in treat-
ing angiogenesis-associated cancers and ocular 
diseases in animal models, and there are multi-
ple ongoing trials analyzing its potential use in 
clinical practice (Folkman. 2007, Chu. 2009, 
Holash et al. 2002). Opposite to VEGF anti-
bodies, VEGF Trap binds all three ligands 
(VEGF-A, VEGF-B and PlGF) of the endogenous 
cell membrane VEGFR-1 and it has thereby been 
suggested to be superior to all anti-VEGF thera-
pies (Chu. 2009, Riely and Miller. 2007). Yet, the 
adverse effects of these substances still some-
what limit the use of them in humans even if 
proven effective in animal models. Thus, the 
novel information on the kinetics of endogenous 
sVEGFR-1 could be of utility in the development 
of new therapeutic tools for diseases associated 
with altered expression of members of the VEGF 
family. 
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Conclusions 
1. Pre-eclampsia is associated with an angiogenic 
imbalance reflecting alterations in anti-
angiogenic markers in the maternal circulation. 
After the onset of the disease, circulating anti-
angiogenic substances, especially sVEGFR-1, are 
found in excess probably reflecting increased 
placental production. In this study, maternal 
serum concentrations of Ang-2, endostatin and 
sVEGFR-1, three central anti-angiogenic mark-
ers, were increased already at 16–20 weeks of 
pregnancy, about 13 weeks before the clinical 
manifestation of pre-eclampsia. Furthermore, 
these biomarkers could be used with a moderate 
precision to identify women at risk of the disor-
der. However, larger patient series are needed to 
determine whether these markers could be ap-
plied for clinical use in the prediction of pre-
eclampsia. 
 
2. Smoking reduces circulating sVEGFR-1 con-
centrations in non-pregnant women, and in 
pregnant women it is likely to reduce the risk of 
pre-eclampsia. In spite of this, we did not find 
statistically significant support to our hypothesis 
that smoking would affect maternal circulating 
sVEGFR-1 or placental sVEGFR-1 expression in 
vitro. However, we cannot exclude the possible 
effect of smoking on placental secretion of 
sVEGFR-1 during the first trimester, a result 
which would be in line with the previous notions 
of altered cytotrophoblast function associated 
with maternal tobacco exposure. 
 
3. The disappearance of endogenous sVEGFR-1 
after pregnancy is biphasic representing a rapid 
half-life of 3.4 h and a slow one of 29 h. The de-
cline in sVEGFR-1 concentrations after mid-
trimester legal termination of pregnancy is ac-
companied with a simultaneous increase in the 
serum levels of free VEGF. Our study provides 
novel information on the kinetics of endogenous 
sVEGFR-1, which could be of interest in the de-
velopment of new therapeutic tools in diseases 
associated with alteration in the members of 
VEGF family. 
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